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Abstract 
 
Tuberculosis (TB), caused by Mycobacterium tuberculosis is the leading infectious 
disease epidemic that claims over 1.6 million lives, while 10 million fell ill in 2017. South 
Africa is burdened with the third highest global incidences following India and China with 
high rates of co-infections with HIV and highest numbers of multi-drug resistant (MDR) 
and extremely resistant (XDR) TB per capita. The current treatment regimen is decades 
old and requires a prolonged period of 6 months. The lack of efficient TB therapy and the 
emergence of MDR and XDR TB, there is an urgent need to find new drug targets for TB 
therapy through understanding the complex host-pathogen interactions. This may then 
lead to pathogen, host-directed therapies (HDT) or adjunct therapies as well as the 
development of effective drugs and drug formulations for the treatment of TB. 
Here we aimed to investigate potential targets for pathogen-and host-directed therapies 
for TB. We screened the anti-mycobacterial activity of 172 minor groove binder (MGB) 
compounds that selectively bind to AT-rich regions of the minor groove of bacterial DNA 
with the helical structure matching that of DNA in Mtb culture. 
Of the 172 total compounds screened 17 hits were identified, of which 2, MGB 362 and 
MGB 364 displayed intracellular mycobactericidal activity against Mtb HN878 at an MIC50 
of 4.09 and 4.19 μM, respectively, whilst being non-toxic. Encapsulation of MGBs into 
non- ionic surfactant vesicles (NIVs) demonstrated a 1.6- and 2.1-fold increased 
intracellular mycobacterial activity, similar to that of rifampicin when compared with MGB 
alone. Treatment with MGB 364 or MGB 364 formulation did not cause DNA damage in 
murine infected macrophages as displayed by low expression of γ-H2Ax compared to 
H2O2 and DMSO. Intranasal administration of MGB 364 and MGB-NIV 364 formulation 
showed one log reduction in bacterial burden with improved pathology and immune 
cytokine production when in formulation. However, intranasal administration of 10 mg/kg 
MGB 362 together with rifampicin had no effect on bacterial loads. In summary, the data 
demonstrate the potential of MGB as a novel class of drug/chemical entity in anti-TB 
therapy and NIVs as an effective delivery system in a novel anti-TB formulation. 
Using deep CAGE and small RNA (CHIP-seq) technologies, International Center for 
Genetic Engineering and Biotechnology’s Cytokines and Diseases lab in collaboration 
with the RIKEN Center for Integrative Medical Sciences (Yokohama, Japan) performed a 
novel transcriptomics study approach by conducting a genome-wide transcriptional 
analyses of RNA transcripts from classically activated macrophages (caMph) and 
alternatively activated macrophages (aaMph) during Mtb infection. We identified host 
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target genes that may play a role in host immune subverting mechanism by Mtb to hide 
away from host effector functions providing a possible target for host-directed therapy for 
tuberculosis. It is postulated that Mtb modulates the transcriptional landscape of IL-4/IL- 
13 alternatively activated macrophages (aaMph) to escape killing by reactive nitrogen 
intermediates (NO) and reactive oxygen species (ROS) functions by IFN-γ stimulated 
classically activated macrophages (caMph). Here we report on the immunoregulatory role 
of IL-4i1, a candidate gene that was upregulated in aaMph during Mtb infection. IL-4i1 is 
a secreted L-amino oxidase with antibacterial properties. The enzyme converts 
Phenylalanine (Phe) into phenylpyruvate releasing toxic products ammonia and hydrogen 
peroxide (H2O2) which in-turn cause immunosuppression of effector T-cells by directly 
inhibiting polarization, proliferation and function or by promoting the generation of Foxp3 
T-regulatory cells. Thus suggesting that IL-4i1 is involved in immune-regulatory 
mechanisms and may be implicated in immune evasion mechanisms by the pathogen. 
Here we report on the role of IL-4i1 on tissue localized T-cell activation and proliferative 
status thus maintaining immune local immune homeostasis. Thus showing that the 
absence of IL-4i1 could cause autoimmunity. To determine the functional role of IL-4i1 
during Mtb infection, IL-4i1 deficient mice and wild-type littermate controls were infected 
with H37Rv and hypervirulent HN878 Mtb strain. IL-4i1 deficient mice were highly resistant 
to both strains of Mtb at 12- and 21-days post-infection as denoted by significant reduction 
in bacterial loads, reduced inflammation, reduced tissue iNOS expression reduced 
recruitment of interstitial macrophages, pro-inflammatory cytokines showed a trend for 
reduction. Interestingly there was a significant increase in NO production in infected 
tissues. There was an increase in M1-like macrophages that correlated with increased 
pro-inflammatory cytokines and chemokines. These data suggested that IL-4i1 regulates 
macrophage-mediated inflammatory responses during acute Mtb infection thus showing 
potential as an immunomodulatory target for TB HDT therapy. The study thus provides a 
framework for new drug targets for the development of new effective drugs and vaccines 
for TB therapy. 
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CHAPTER 1 
 
LITERATURE REVIEW 
 
1.1 Tuberculosis 
Tuberculosis (TB), a deadly epidemic caused by the widely spread pathogen, 
Mycobacterium tuberculosis (Mtb), remains a major global challenge responsible for many 
ill healths and deaths among millions of people each year [1]. Approximately one-third of 
the world’s population is infected with Mtb. South Africa is burdened with the third highest 
global incidence of this deadly epidemic after India and China, high rates of co-infections 
with HIV and highest number of multi-resistant and extremely resistant tuberculosis per 
capita [1, 2]. An estimate of over 10 million of the world’s population had developed TB in 
2017, an estimated of 1.6 million deaths were due to the disease [1]. The high rates of 
multi-drug resistant (MDR) and extremely drug-resistant (XDR) TB development over the 
current TB regimen, propels an urgent need to find new therapeutic strategies for the 
treatment of TB [3, 4]. 
 
1.2 Current treatment challenges 
The current regimen for drug-susceptible Mtb is decades-old. It involves a strict 
compliance phase to a cocktail of four drugs containing rifampicin (RIF), isoniazid (INH), 
pyrazinamide (PZA), and ethambutol (EMB), followed by a longer phase that involves RIF 
and INH [5]. The current regimen lasts up to six months and is effective provided full 
compliance by the patient [5, 6]. The major challenge associated with this regimen is the 
duration which makes it difficult for patience compliance, thus immensely contributing to 
the development of MDR and XDR Mtb strains because of dormant Mtb bacilli since the 
current regimen focuses on the target’s bacterial replication [7]. To help facilitate the 
compliance to the current regimen, in 1991 WHO implemented the Directly Observed 
Therapy short course (DOTS) program [5, 6]. The program included case detection by 
sputum-smear microscopy, government commitment to TB control, regular supply of 
drugs, supervised treatment, and reports on the progress of the health system. However, 
due to inadequate diagnostics and treatments, DOTS was only effective to 45% of globally 
estimated TB cases [5]. Furthermore, HIV/AIDS and TB co-infections have contributed to 
an increased prevalence to TB incidences which increase the number of MDR cases. The 
current treatment for MDR can last up to 2 years and this involves the use of toxic less 
effective second- or third-line drugs that are not readily available in endemic areas [5, 7]. 
Thus, confirming an urgent need for new drug discoveries for the treatment of TB that 
ideally would have novel mechanism of action; rapid bactericidal activity; optimized 
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pharmacokinetic/pharmacodynamic (PK/PD); low potential for drug–drug interactions and 
an excellent safety profile [6]. 
 
1.3 Treatment strategies 
Several advances are in the pipeline for the development of new drugs and vaccines for 
the treatment of TB. The complex interplay between host and pathogen has resulted in 
different approaches to identify drug targets for TB therapy. Using genomic and functional 
data analysis have identified host-pathogen inter and intra genes that could be potential 
drug targets for TB treatment [8]. Furthermore, several candidates of mycobacterial 
agents are on phase II and phase III of clinical trials. The STOP-TB partnership which was 
established in 2000 aims to eliminate tuberculosis as a public health problem through the 
development of new TB diagnostics, new drugs, new TB vaccines and new TB biomarkers 
[9]. In recent years the approval of bedaquiline and delamanid for treatment against MDR 
and XDR have shown promise for the development of more effective drugs [6, 10, 11]. 
However, some adverse effects were noted for these drugs including hERG toxicity which 
indicated the need for identification of different target agents for TB therapy [6]. Recent 
advances have used different strategies to identify useful targets through their different 
modes of actions through different screening methods [6]. For example, SQ109 an 
inhibitor of Mycobacterial membrane protein Large (Mmp) 3 which is an export protein 
important for the transportation of metabolites from the cytosol of Mtb [12]. Therefore, 
SQ109 acts by blocking the protein that is important for Mtb survival. One crucial step to 
achieving STOP-TB partnership 2050 goals is through the understanding host-pathogen 
interactions [4, 9]. The recent global complementary approach focuses on developing 
adjunct host-directed therapies [4, 13]. This aims at dissecting the immunological 
pathways involved in killing Mtb and how Mtb subverts and hides from this protective 
immune response for its survival [4, 13]. Targeting of host-factors may lead to identifying 
possible drug targets that may reduce inflammation, tissue damage, preserve lung 
function and enhance effectiveness of TB therapy leading to the development of effective 
drugs against Mtb and drug-resistant TB [4, 14]. Several classes of repurposed drugs 
have been identified as host-directed candidates for TB therapy. These include vitamin D, 
Metformin, Statins, Prostaglandin E2 among others [4, 15-18]. These drugs target a vast 
range of host immune responses against Mtb, including the release of innate antimicrobial 
peptides such as cathelicidin [19], enhancing autophagy, promoting phagosome 
maturation [20] and targeting host cholesterol/lipid metabolism [17]. Other host target 
candidates include various classes of coding and non-coding genes involved in host 
immunity Mtb. Examples include microRNAs, long non-coding RNA and transcription 
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factors which have important roles in regulating gene expression cellular pathways 
involved in immune regulation against Mtb or could be used as biomarkers for TB 
progression [4, 21-23]. 
 
1.4 Minor groove binders as pathogen direct therapy for TB 
 
1.4.1 Structure and binding selectivity 
Minor groove binders (MGB)s are a large class of compounds from the family Lexitropsins 
[24]. These are small molecules that have a helical structure that matches the curvature 
of DNA at the minor groove and thus strongly bind and form complexes with the minor 
groove of DNA [25]. Binding selectivity of the minor groove compounds with respect to the 
DNA base sequence it binds to depends on the structure of the compound [25, 26]. 
 
     Figure 1.1  Graphical representation of a minor grove binder. [24] 
 
Natural forms of MGBs such as the aromatic diamidines, pentamidine prefer binding at 
AT-rich regions of the minor grooves of DNA [27]. Their mechanism of action include 
interfering with gene transcription that controls DNA replication and topoisomerase 
inhibition [28]. The synthesis of several classes of minor groove binders from the 
University of Strathcylde (S-MGB) have shown activity against a range of infectious 
diseases [28]. Derived from the natural product distamycin, the many variations in the 
head to tail structure of S-MGB have shown successful selectivity against a wide range of 
infectious diseases [24, 28-30]. The current S-MGBs library which contains over 400 
compounds, was made by varying several components of the structure of distamycin, 
these changes included a less basic functional group that replaces the amidine at the C- 
terminus (tail group). Methyl groups were replaced by larger alkyl side chains while body 
is made of and thiazole rings. The formyl group from distamycin was replaced by aromatic 
rings and the N-terminal amide has been replaced by its isosteric alkene [24, 28, 31] 
(Figure 1.1). The selectivity and activity against infective agents were linked to the 
structure and binding affinity to DNA. The different structural features based on charge 
and lipophilicity 
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are deemed essential for selectivity of penetration through cell walls of target organism. 
For example, Trypanosoma congolense was attributed to replacement of a pyrrolyl with 
phenyl/pyridyl [25], and for Gram-positive bacteria the isosteric replacement of a amide 
with an alkene, the replacement of a pyrrolyl with phenyl group and the inclusion of a less 
basic morpholine tail group were important [26]. 
 
1.4.2 Minor groove binders against parasitic diseases 
Minor groove binders have been used against parasitic infections for decades. For 
example, the use of bisamidine, pentamidine and diminazene have been used for 
treatment against Human African Trypanosomiasis (HAT) and Animal African 
Trypanosomiasis (AAT) [32, 33]. The activity of furamidine and pentamidine against 
trypanosoma or plasmodia have been associated with DNA binding with specific affinity 
for AT-rich regions of parasitic minor groove of DNA [31]. The mechanism involved was 
linked to the destruction of the parasitic kinetoplast minicircles which are predominantly 
AT-rich, within 24 hours of exposure to pentamidines and furamidines [28, 33]. S-MGBs 
were studied for their activity against Trypanosoma brucei brucei. Modifications in the 
head and in the number of heterocycles were made upon synthesis to these compounds. 
The head group was linked by an amide, an amidine, or an alkene and the number of 
heterocycles between the head and the tail group was either two or three. Four 
compounds showed anti-trypanosoma activity in a nanomolar range and this was 
attributed to the alkene and amide linked head groups [34]. In vivo activities of these MGB 
compounds have been shown in mice infected with T. congolense [35]. MGBs with an 
alkene link between the two N-terminal building blocks showed nanomolar activity range 
against chloroquine sensitive (3D7) and resistant strains (Dd2) of Plasmodium falciparum 
infections. Most of the active compounds were those containing a C-alkylthiazole building 
block [36]. 
 
1.4.3 Minor groove binders against fungal diseases 
Classes of MGBs have also been investigated against fungal infections by Candida 
albicans (C. albicans), C. neoformans and Aspergillus fumigatus (A. fumigatus). Many of 
which have shown cross reactivity with other anti-parasitic and anti-bacterial activities 
[28]. Analogues of pentamidines and di-cationic substituted bis-benzimidazoles, derived 
from classes of compounds that have excellent activity against several protozoan 
pathogenic organisms, showed potent fungal activity C. albicans and C. neoformans and 
other fungal species [37]. S-MGB compounds showed selective activity against C. 
neoformans over C. albicans and this activity was attributed to the insufficiency of the 
single interaction of cationic tail group from the tested compounds with the negatively 
charged phosphodiester 
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anion on the cell wall of C. albicans which allows the penetration of the MGB in the cell 
wall. Furthermore, the observed anti-fungal activities matched that against 
Staphylococcus aures (S. aures) [29]. Most of the active compounds were associated with 
the isoquinoline head group that potentially contributed to the threshold lipophilicity 
necessary for the observed activity [29]. Currently, these studies have advanced to in vivo 
“proof of concept” animal studies (unpublished data from Suckling and Scott groups). 
 
1.4.4 Minor groove binders against bacterial diseases 
Identification of an active molecular structure showing antibacterial properties requires a 
series of steps to verify a target as active. These steps include measurement of MIC and 
MBC; activity against a series of bacterial strains; measurement of static activity; potential 
to cause resistance and solubility, stability and formulation issues. A candidate successful 
of these steps is warranted for “proof of concept” studies that involve in vivo testing in 
animal models [28]. Distamycin A, GSQ 1530 has been reported for activity against gram- 
positive staphylococci species that include S.aureus; S. epidermidis and S. haemolytics 
when tested against 73 clinical isolates [38]. In vitro killing kinetic study revealed a 3-log 
reduction of bacterial growth within 6h after exposure [38]. One S-MGB is currently 
undergoing phase IIa clinical trial for treatment of Clostridium difficile in partnership with 
MGB Biopharma. The compound consisting of a head group with a stilibene-like moiety 
and a body that consists of two N-methylpyrroles attached to an aminoethyl morpholine is 
active against Gram-positive bacteria [24, 26, 30]. 
 
1.4.5 Minor groove binders against antimycobacterial tuberculosis diseases 
 
Distamycin analogues have been evaluated for their activity against Mycobacterium 
tuberculosis. Khalaf et al. [24] found that, replacing the N-terminal pyrrole-formamido 
moiety of Distamycin with biarryl units improved DNA sequence-selectivity binding for anti- 
mycobacterial activity [24]. Thiophene motif-containing polyamide exhibited a 10-fold 
increased Mtb compared to distamycin [39]. Our preliminary screenings of S-MGB 
compounds showed micromolar activity against Mtb without being toxic to mammal cells 
due to the substitution of the pyrrole group with a thiazole group which improved 
liphophilicity and increased binding affinity [29]. The identified structural features indicate 
an important class of minor grove binders that warrant hit to lead optimization for 
antimycobacterial activity [29]. 
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1.5 Drug delivery systems 
 
1.5.1 Nanoparticles 
The use of nanoparticle drug delivery systems to the site of infection have been 
considered an important tool for the treatment of pulmonary TB in their advantage to 
encapsulate multiple hydrophilic and hydrophobic drugs. Nanoparticles are structures with 
sizes ranging from 1-100nm with unique physiochemical and chemical properties thus 
possessing favourable material for biomedical applications [40]. Strategic drug 
conjugation either through covalent linking or encapsulation is important for the outcome 
of targeted therapy. Cell-specific targeted approach through special carriers conjugated 
with recognition ligands at the surface of cells is aimed at retaining the drug longer at the 
site of infection [40, 41] mainly targeting alveolar macrophages which are used as a 
harbour by mycobacteria for prolonged survival. Furthermore, this would reduce 
systematic toxicity. A single dose of inhaled formulation would reduce the number of oral 
daily doses and thus improve patient compliance [42]. Oral therapy is still effective, but 
several patient relapses and drug resistance have been attributed to the high drug dose 
with multiple drugs. A single retainable prolonged low dose treatment shows potential for 
an effective treatment strategy. 
 
1.5.2 Liposomes 
Liposomes are the first class of drug carriers to be investigated. These are 
nano/macroparticles or colloidal spherical ranging from 80-300nm in size [40]. They are 
composed of phospholipids and steroids, bilayers and enclose a discreet aqueous spaces 
and other lipids which aids them to increase drug solubility and pharmacokinetic 
properties, cellular uptake and biodistribution to target sites in vivo [43, 44]. The major 
advantage of liposomes is that they can entrap both hydrophilic in the aqueous layer and 
hydrophobic molecules in the lipid bilayer. Their biocompatibility and self-assembly 
capability, ability to entrap several drug loads as well as the easy manipulation of their 
physiochemical and biophysical properties has shown favour towards their use as delivery 
systems for many biomedical applications [44]. Generally four classes of liposomes have 
been reported; conventional liposomes; sterically stabilized liposome; ligand-targeted and 
a combination of all types which are employed according to intended therapeutic use 
ranging from gene therapy, drug molecules, bioactive drugs, and adjunct therapy (Figure 
1.2) [44]. Conventional liposomes face various defense challenges that are aimed at 
removing foreign particles from the body. These include reticuloendothelial system 
(RES); opsonization and immunogenicity [44]. To counter such challenges to improve 
permeability, effective treatment, reduce RES clearance and minimize toxicity, modified 
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forms of liposomes with changes in lipid composition, charges and the addition of cell 
surface ligands have been synthesized and investigated in vitro and in vivo for biomedical 
use [44]. For example, Antisense oligodeoxynucleotides (AsODN) with therapeutic 
efficiency against lung cancer when encapsulated into dendrosomes, a specialized form 
of liposomes, showed high suppression of target gene PKC-α in lung cancer cells with no 
apparent toxicity in vitro [45]. Mannosylated liposomes targeted at mannose receptor at 
alveolar macrophages have been used for the treatment of respiratory intracellular 
parasitic infection [46]. Mannosylated liposomes with 4-aminophenyl-a-d- 
mannopyranoside (particle size:1000nm) were used to encapsulate ciprofloxacin. 
Pulmonary administration of the mannosylated CPFX-liposomes improved targeting 
efficiency was significantly greater than CPFX in unmodified liposomes [46]. Liposomes 
have also been used for delivery of anti-TB for treatment in vitro and in vivo also following 
targeted approach [41, 42, 47, 48]. Encapsulation of first-line anti-TB drugs isoniazid and 
rifampicin into stealth liposomes improved Mtb clearance compared to free drugs following 
6 weeks bi-weekly injections in mice. Liposome-encapsulated drugs at and below 
therapeutic levels reduced bacterial loads in lungs, spleen and liver significantly compared 
to free-drugs while being non-toxic [49]. Pandey et al. (2004) [50] reported on the 
efficiency of lung specific stealth liposomes encapsulated with rifampicin (RIF) and 
isoniazid (INH) intravenously administered to guinea pigs weekly for 6 weeks. Treatment 
with drug formulation sustained drug bioavailability for 96-168 hr in plasma, while tissue 
drug levels were retained for up to 7 days, a 2.9-4.2-fold increase compared to free drugs. 
Following 6 weekly treatments, Mtb clearance was improved in liposomal drugs compared 
to free drugs [50]. A single nebulization of liposomal INH and RIF maintained therapeutic 
plasms drug levels from 45mins to 48hrs and up to 5-days in lung tissue and alveolar 
macrophages, whereas drugs were cleared within 24hrs post-nebulization in free-drug 
treated guinea pigs [51]. Recently, Cheng and Schorey, (2019) used liposomes to deliver 
Mtb RNA derived from extracellular vesicles of Mtb-infected macrophages that activated 
RNA sensor signalling for IFN-β production, a mechanism that showed efficiency in 
adjunct therapy when combined with moxifloxacin in vitro and in vivo for Mtb treatment 
[48]. The shortfall for the use of liposomes as delivery systems in the clinical practice is 
associated with the technology and manufacturing costs, stability of formulations and 
quality assurance [42, 44, 47]. 
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Figure1.2: Representation of different types of liposomal drug delivery systems derived 
from [44]. There are for types of liposomes A) Conventional liposome B) PEGylated liposome C) 
Ligand-targeted liposome and D) Theranostic liposomes each with its own characteristics 
advantages and disadvantage. 
 
 
1.5.3 Non-Ionic Surfactant Vesicles (NIVs) 
Non-ionic surfactant vesicles (NIVs), small colloidal particles which are composed of a 
non-aqueous, non-ionic surfactant bilayer surrounding a central aqueous compartment 
are a better alternative to liposomes in that they are thermodynamically stable, they can 
be easily manufactured, size can be altered easily, they have flexible storage conditions 
and are cost-effective (Figure 1.3) [52]. Generally, they are less toxic, less hemolytic, 
less irritating to cell surfaces and stable at physiological pH in solution [52]. NIVs have 
been evaluated in several studies in the treatment of infectious diseases. A study to 
evaluate the use of NIVs as a delivery system on pulmonary treatment of fungal infection 
showed that amphotericin B (AMB), used for the treatment of fungal and leishmania 
infection had a significantly higher efficiency when encapsulated into NIVs. (AMB)-NIV 
delivered by nebulization, significantly reduced fungal lung burdens in rat model of 
invasive pulmonary Aspergillosis compared with carrier alone [53]. AMB-NIV reduced 
Leishmania donovani liver burden compared to AMB alone, however had no effect on the 
formation of cutaneous Leishmania major lesions without being toxic to host [54]. Single 
dose treatment with nonionic surfactant vesicle formulation of sodium stibogluconate 
(SSG-NIV) against visceral leishmaniasis significantly suppressed spleen and bone-
marrow parasite burdens compared to SSG free drug in BALB/c mice [55]. In study to 
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evaluate the release efficiency of different types of NIVs that were encapsulated with 
Ciprofloxacin (CPFX) based on the methods of preparation, Akbari et al. (2015) showed 
that all formulations of CPFX had higher antibacterial activity compared to free CPFX 
solutions. However, there have not been studies on the use of NIVs as delivery systems 
in the treatment of Mtb infections [56]. 
 
 
  
 
 
Figure 1.3: Schematic representation of a non-ionic surfactant vesicle (noisome) derived 
from [52]. Niosomes contain an inner and outer the compartment, the inside is made up of an 
aqueous compartment while the outer compartment is made up of a lipid bilayer. 
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1.6 Host targets for host-directed therapy 
 
1.6.1 Pathogenesis and Immunity of Mtb 
Mtb is transmitted through the inhalation of aerosol droplets containing tubercle bacilli 
from an individual with active pulmonary TB disease. The bacilli migrate to alveoli where 
they are encountered by alveolar macrophages [57]. The bacterium is rapidly 
phagocytosed by macrophages through recognition by pathogen recognition receptors 
(PRRs) and toll-like receptors (TLRs) ligands. The bacterium is then captured in 
phagosome which later fuses with the lysosome, matures and kills the bacterium [57, 
58]. The host cell is then stimulated to produce pro-inflammatory cytokines such as 
tumour necrosis factor (TNF, IL-6, IL-1α, IL-1β, IL-12 and IL-18) and chemokines which 
drive the recruitment of more leukocytes to the site of infection via the MyD88 dependent 
and independent activation of NFκB signalling [57]. Neutrophils and monocytes are 
recruited first to help form and organize foamy granulomas, followed by dendritic cells 
which also engulf and phagocytose the bacterium into antigen (Ag) which is crucial for 
antigen presentation. Dendritic cells then migrate to regional lymph nodes where they 
present the processed antigens to lymphocytes via the major histocompatibility complex 
class II (MHCII) [59]. Lymphocytes are then recruited to the site of infection following cues 
from antigen presentation and cytokine release [59-61]. This leads to the formation of 
organized granulomas for containment of infection, consisting of infected macrophages at 
the centre surrounded by epithelioid macrophages, foam cells and recruited lymphocytes 
and fibrous capsule [60, 62]. However, granulomas undergo necrosis over time, the dead 
macrophages form caseum at the centre allowing Mtb to survive within macrophages 
extracellularly within the granuloma [60, 63]. This increases the chances of Mtb escape 
and spread into airways and other areas of the body (Figure 1.4) [63]. 
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Figure 1.4: Pathogenesis, immunity and dynamics of granuloma formation upon Mtb 
infection. Adopted from [64]. Mtb transmission through aerosol droplets into alveolar 
macrophages. Pathogen recognition receptors (PRR) are stimulated through the recognition of 
pathogen associated molecular patterns (PAMPs). Macrophages are then stimulated to release 
chemokines and cytokines which drive the recruitment of leukocytes to site of infection to drive 
innate and adoptive immunity which leads to the formation of granulomas. 
 
 
1.6.2 Mycobacterium tuberculosis in macrophages 
 
1.6.2.1 Macrophage activation 
Subsequent to phagocytosis of Mtb, macrophages are polarized into distinct subtypes, 
IFN-γ classically activated macrophages (caMph or M1) and IL-4/IL-13 alternatively 
activated macrophages (aaMph or M2) upon activation by different activation stimuli [65] 
Thus, suggesting that the different subsets of macrophages engage in distinct induction 
pathways and responses to Mtb infection. 
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Figure 1.5: Macrophage polarization into distinct phenotypes following various stimuli. 
Adopted from [66]. Due to the cascade of various environmental and cytokine cues, monocytes 
turn into highly microbicidal classically activated (M1) or alternatively activated immunosuppressive 
(M2) phenotype. 
 
 
1.6.2.2 Classically activated macrophages (caMph/M1) 
Classically activated macrophages (caMph or M1) are characterised by increased 
microbicide activity marked by the expression of nitric oxide synthase 2 (iNOS), high Ag 
presentation associated with increased MHC class II expression and the production of IL- 
12 [65]. This is dependent on nuclear factor κB (NF-κB) pathways in response to pro- 
inflammatory cytokines such as IFN-γ stimulus via IFN-γ receptor (IFN-γR) together with 
the binding of microbial products such as lipopolysaccharides (LPS) leading to the 
production of nitric oxide (NO) through iNOS expression [65]. iNOS converts L-arginine 
into reactive nitrogen intermediates (RNI) resulting in NO bacterium and mycobacterium 
killing (Figure. 1.5) [65] . 
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During Mtb infection, the production of pro-inflammatory cytokines and RNS is critical for 
the inhibition of growth and clearance of the pathogen [65]. Mice deficient of the 
proinflammatory cytokines such as TNF-α, IL-1 and IL-12 which are released by caMph 
and essential for granuloma formation, creating an environment for containment of 
infection, were reported to succumb to infection before wild-type (WT), had an increased 
disease burden and dissemination of bacteria to different organs [67-70]. 
Likewise, Scanga et al. reported an increased and rapid replication of Mtb in iNOS 
knockout mice compared to wild-type mice [71], implying a significant role for NO in host 
defence against Mtb. Furthermore, macrophages found at the centre of granulomas have 
a more proinflammatory phenotype compared to those at the periphery, with higher 
expression of iNOS compared to arginase-1 [72]. In the absence of NOS-2, mice deficient 
of NOS-2 developed large liver and spleen granulomas at four weeks post infection due 
to an accumulation of macrophages following infection with Mycobacterium bovis. 
However, these macrophages had a decreased acid phosphatase activity as well as 
decreased epithelioid differentiation compared to wild-type mice, suggesting a role for NO 
in macrophage activation [73]. At 6 weeks post infection, lung and spleen granulomas of 
nos-2 deficient mice had become larger compared to that of wild-type mice and had 
developed large central cavities surrounded by necrosis that were associated with a 
number of acid-fast bacilli, thus displaying an exacerbated yet inefficient cellular immune 
response due to the absence of NOS-2 which then led to tissue damage [74]. Taken 
together, essentially these findings emphasise the instrumental role of caMph and RNS in 
the eradication of mycobacterial infections. 
 
1.6.2.3 Alternatively activated macrophages (aaMph/M2) 
Alternatively activated macrophages are activated by anti-inflammatory cytokines 
produced generally in Th2 responses against allergic, cellular and humoral responses to 
parasitic and extracellular pathogens, IL-4 and IL-13 via the IL-4 receptor alpha chain (IL- 
4Rα) and STAT 6 signalling (Figure. 1.5) [75-77]. Alternatively, activated macrophages 
are described as a mechanism by which Th2 responses reduce excessive inflammation 
resulting in moderate inhibition of proinflammatory responses, upregulation of mannose 
receptor and MHC II presentation and the production of Arginase 1 (Arg1) [75-77]. 
While the role of caMph against bacterial and mycobacterial infections like Listeria 
monocytogenes and Mtb infections is well established, the role of aaMph is less defined 
and requires further investigation. In contrast to the killing of Mtb as a result of NO 
production, aaMph induces the production of Arginase-1 (Arg-1) which competes with 
iNOS for L-arginine, resulting in decreased NO production [75, 77]. This suggests a 
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potential evasion mechanism by which Mtb hides in aaMph to avoid effector killing 
functions by caMph. 
Other studies have shown the expression of Arg1 obtained from human macrophages and 
type II pneumocytes obtained from lung granulomas of TB patients and HN878 infected 
murine macrophages [78]. Other studies have also shown Mtb to interfere with the 
polarization of caMph by secreting virulence factor early secretory antigenic target 6 
(ESAT6) which is employed in the lysis of phagolysosomal membrane causing 
translocation of Mtb to the cytoplasm of myeloid cells, thus restricting the MyD88- 
dependent TLR signalling [78, 79]. Recently Guler et al. showed that the virulent clinical 
Mtb strains induce Arg1 production in aaMph independent of the IL-4Rα in aaMph 1[80]. 
While aaMph may be essential for host protection against parasitic and extracellular 
pathogens, Mtb strategically uses aaMph to hide from host protective functions. It is thus 
hypothesized that Mtb potentially modulates the transcriptional landscape of aaMph to 
escape and survive host-effector responses [80]. However, this subverting strategy 
mechanism is not well understood. 
 
1.6.2.4 Candidate genes upregulate in alternatively activated macrophages during 
Mtb infection: IL4i1. 
 
In collaboration with RIKEN Center for Integrative Medical Sciences (Yokohama, Japan), 
our lab conducted a novel transcriptomics study approach by performing a genome-wide 
transcriptional analyses of RNA transcripts using deep CAGE) technology aiming at 
identifying candidate genes that are upregulated in aaMph during Mtb infection as an 
evasion strategy by Mtb [81-83]. RNA transcripts obtained either from caMph or aaMph 
infected with HN878, a hypervirulent strain of Mtb responsible for high TB mortality rates 
and reduced host resistance, were used to identify the candidate genes (Figure 1.6). 
Among he identified candidate genes was the L-phenylalanine encoding gene, Interleukin 
4 inducible (IL-4i1) gene 1 (Figure 1.7) [83]. 
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Figure 1.6: Layout of CAGE experiment. Bone marrow-derived macrophages (BMDM) were 
differentiated for 10 days in culture medium followed by treatment with either recombinant IFN-γ, 
IL-13, IL-4 or with a combination of IL-4/IL-13. Following stimulation, macrophages were incubated 
for 24 hours followed by restimulation and infection with HN878 Mtb strain at 4 hours post re- 
stimulation. RNA was then isolated at 0, 2, 4, 6, 12 and 24 hours post initial stimulation and 4, 12, 
24, 48 and 96 hours post-infection to determine mRNA transcripts for IL-4i1 using CAGE tags. Top 
graphs in each replicate represent Mtb-infected macrophages while bottom represents uninfected 
macrophages. 
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Figure 1.7: IL-4i1 mRNA expression profile in. Adopted from Cage data. IL-4i1 is highly 
upregulated in IL-4 of IL-4/IL-13 macrophages at 4-6hr post-stimulation and 4hr post-infection. 
 
1.6.2.5 IL-4i1 expression and activity 
IL-4 inducible gene 1 was primarily characterized as an IL-4 activated gene expressed in 
murine and subsequently in human B-cells [84]. High expression levels of the gene were 
further demonstrated in primary mediastinal B-cell lymphoma (PMBL) which was further 
described in professional antigen presenting cells (APCs), mature dendritic cells and 
macrophages [74, 84]. However, there has been contradicting evidence on the expression 
stimulus that triggers IL-4i1 expression on B-cells and that which triggers expression in 
APCs [85, 86]. Contrary to IL-4 stimulation in B-cells and results obtained from the CAGE 
data, IL-4i1 was shown to express under proinflammatory and Th1 (IFN-γ) mediators in 
macrophages and dendritic cells in vitro [86]. Human monocyte-derived macrophages and 
monocyte-derived dendritic cells displayed five-fold higher IL-4i1 expression and activity 
in response to IFN-γ and no activity when stimulated with IL-4 whereas B-cells displayed 
a two-fold activity in response to IL-4 [86]. Furthermore, immunohistochemistry of Th1 
granulomas biopsies obtained from sarcoidosis or TB patients revealed 80% IL-4i1 
expression in regions concentrated in macrophages and dendritic cells compared to Th2 
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granulomas obtained from schistosomiasis patients [86]. This suggests that IL-4i1 is 
implicated in the regulation of inflammatory responses [85, 87]. 
Most recently IL-4i1 expression was reported in Th17, conventional memory CD4+ T cells, 
and human inducible regulatory T (Foxp3+ iT-reg). The expression of IL-4i1 in Th17 cells 
was attributed to its role in the transdifferentiation of these cells to iT-regs in order to 
maintain cell-cycle progression of this cell type [88]. The expression of IL-4i1 in iT-regs 
was characterised by the expression of the transcription factor Aiolos, a member of the 
Ikaros family which is involved in the differentiation of Th17 and iT-regs cells [87]. 
However, IL-4i1 did not express in cells expressing Helios, another transcription factor of 
the Ikaros family which identifies natural Foxp3+ T-reg cells from thymocytes [87]. This 
suggests a close relationship between Th17 cells and iT-regs and thus a role for IL-4i1 
under functional roles of these cell types. Because the murine IL-4i1 is an orthologue of 
the human IL-4i1 (hIL4i1), which map to chromosome 7 and 19 respectively, these genes 
share many similarities in their functional roles as demonstrated in most studies [74, 87]. 
The expression profile of IL-4i1 may provide insight on its immune regulatory function. 
 
 
Figure 1.8: Functional role of IL-4i1 in immune regulation. Expression of IL-4i1 in 
macrophages is driven by different stimuli in human and murine macrophages. IL-4i1 is 
expressed under inflammatory conditions marked by IFN-γ, LPS and TLR mediated responses 
whereas in murine macrophages, IL-4i1 expression is stimulated through IL-4Rα signaling via 
STAT-6 phosphorylation. The expression of the gene IL-4i1 codes for the secretion of the 
enzyme, which through its enzymatic activity presents antibacterial properties and immune 
regulatory properties. 
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             1.6.2.6 Functional role of IL-4i1 in immune responses 
 
IL-4i1 is a secreted L-amino acid oxidase which acts by degrading essential amino acid 
phenylalanine (Phe) to produce toxic products, phenylpyruvate, H2O2 and ammonia which 
provide a hostile environment for bacterial growth, presenting antibacterial properties at 
both physiological and acidic conditions [84, 85]. Mason et al. reported IL-4i1 to have an 
acidic pH and lysosomal localisation preference which was unusual for an L-amino acid 
oxidase which is normally most active at physiological pH [84]. However, Boulland et al. 
showed optimal IL-4i1 activity is at physiological pH and temperature similar to other L- 
amino acid oxidases [89]. This suggests colocalisation between lysosome and cytoplasm 
to confer an increased enzymatic activity and antibacterial properties. 
On the other hand, this enzymatic activity has been implicated in immune suppression 
activities through the downregulation of TCR complex ζ chain expression via the 
production of H2O2 thus inhibiting T-cell proliferation [89]. Lasouadris et al. further reported 
this immunosuppressive effect in antitumor T-cell response in vivo. Transgenic mice 
injected with cells expressing IL-4i1 developed tumours more frequently than control mice 
and had a reduced number of IFN-γ producing cytotoxic antitumour cells [90]. In line with 
these findings, analysis of T-cell differentiation from conventional splenic CD4+ (GFP- 
CD25+CD62L+) cells from Foxp3-EGFP transgenic mice cultured with IL-4i1 expressing 
or HEK control cells and naive CD4+ cells from PBMC cultured with THP1 or THP1-IL-4i1, 
showed that IL-4i1 stimulates the generation of FoxP3+ regulatory (T-regs) from mouse 
and human T-cells through the ablation of mTORC1 kinase signaling pathways in 
activated CD4+ T cells while limiting the differentiation of T-effector (Th1 and Th2) [91]. 
Recently, IL-4i1 has been reported to play a role in the polarization of macrophages to an 
M2 phenotype which supresses T-cell proliferation via a mechanism that involves STAT- 
6 and STAT-3 phosphorylation and in part through the L-tryptophan and L-arginine 
depletion [92]. Depletion of IL-4i1 resulted in enhanced B-cell activation through activation 
of BCR via BCR Syk-Akt-S6 kinase activation pathway [93]. In vivo studies have identified 
CD8 T-cells anti-proliferative role of IL-4i1 in a tumour model. In a spontaneous in vivo 
melanoma model in IL-4i1 knockout mice lead to delayed tumour progression 
accompanied by an infiltration of Th1 cell and CD 8 T-cell [94]. In a multiple sclerosis 
model, IL-4i1 showed increased T-cell proliferation in the brain and peripheral tissues. 
However, in the presence of IL-4i1 T-cell expansion was reduced and recruitment of and 
survival of oligodendrocytes was increased, thus showing the importance of IL-4i1 in 
remyelination [95]. 
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Since T effector cell functions play a crucial in the eradication of pathogens, the T-eff:T- 
reg balance is critical for immunological homeostasis. Although the primary function is for 
the maintenance of immune homeostasis, T-reg cells have been associated with immune 
suppressive activities that block eradication of pathogens by pathogen-specific T-cells 
thus causing persistence of infection. The accumulation of FoxP3+ T-reg cells in lung 
granulomas and pulmonary lymph nodes of Foxp3-GFP mice following an aerosol 
infection with Mtb suggested a suppressive capacity for T-regs on Mtb control [96]. 
Furthermore, mice depleted of T-regs were displayed a one log reduction in Mtb bacterial 
load. Recently, IL-4i1 has been employed as a biomarker for cancer prognosis in 
cutaneous melanoma patients. The location of IL-4i1+ cells was positively correlated with 
T-regulatory cells and inversely correlated with the presence of CD8+ anti-tumour T-cells 
supporting the role of IL-4i1 in immune evasion. Molinier-Frenkel et al. [97] showed that 
single amino-acid induced by either single-nucleotide polymorphisms (SNPs) or acquired 
mutations may affect enzymatic activity, that could cause alteration in IL-4i1 
immunosuppressive capacity. SNP R102G of exon 4 of isoform of IL4i1 gene which is 
expressed in lymphoid tissues exogenously caused hypomorphic mutant of IL4I1 
production in tumour macrophages, N92D SNP expression caused hyperactive IL4I1 
production. These data showed that the expression of these SNP may predispose patients 
to defective anti-tumour T-cell responses, with favourable and unfavourable 
consequences on patients’ prognosis, respectively. The expression of the hyperactive 
enzyme could protect from the development of an autoimmune disease, while a 
hypomorphic enzymatic activity may predispose to autoimmunity [97]. 
Although shown to have antibacterial properties and a well-defined role in tumour 
pathology, little is known about the role of IL-4i1 on the immunity against pathogenic 
infections. To determine the function of IL-4i1 on T-cells during Mtb infection in vitro, an 
L-amino acid oxidase non-specific blocker, benzoic acid was used to block the IL-4i1 
expression in macrophages in vitro. Co-culturing naive T-cells with macrophages 
stimulated with blocked IL-4i1 expression resulted in increased T-cell proliferation and 
decreased bacterial burden compared to control cells expressing IL-4i1 [unpublished 
data]. In light of these findings, it was suggested that the enzyme IL-4i1 which participates 
in T-reg enrichment and M2 macrophage polarization may apply its immunosuppressive 
activity on T-cells both by direct inhibition of effector cell proliferation and by indirect 
immune regulation mediated by FOXP3+T-reg cell induction [91] or through the promotion 
of alternatively activated macrophages in the case of Mtb. Thus targeting IL-4i1 could 
potentially help dissect its role and mechanism in immunopathology during Mtb infection. 
Furthermore, while the role of IL-4i1 on immune homeostasis has been studied under 
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inflammatory conditions and tumour environment, studies on SNPs and mutations of the 
gene suggest a possible role for IL-4i1 on the development of autoimmunity in vitro. 
However, no studies to date have reported on the role of IL-4i1 on the maintenance of 
immune homeostasis at steady state in vivo. 
 
1.7 Study aim, objectives Overall study aim: 
To identify potential novel drug targets for pathogen- and host-directed therapy for 
tuberculosis. 
Pathogen-directed therapy: 
Aim 
The main of this study was to identify the anti-mycobacterial activity of minor groove binder 
(MGB) compounds as novel anti-TB drugs and a foundation in the development of a novel 
inhalable drug formulation for the treatment of tuberculosis. 
Objectives 
 
 
1. To screen a diverse range of S-MGB classes for their anti-mycobacterial tuberculosis 
activity in vitro in culture. 
2. Provide lead compounds that will be further evaluated for their intracellular anti- 
mycobacterial activity and cytotoxicity. 
3. Encapsulate lead compounds into NIVs and evaluate for improved efficacy in murine 
macrophages. 
4. Biological profiling of lead compounds in vivo in acute Mtb-infected murine models. 
 
Host-directed therapy: 
Aim 
 
To determine the functional immune regulatory role of IL-4i1 during steady state and 
Mycobacterium tuberculosis infection through loss of function approach in mice. 
 
Objectives: 
 
1. Characterization of IL-4i1 deficient mice models. 
2. To determine the role of IL-4i1 on immune homeostasis at steady state. 
3. To determine the role of IL-4i1 during acute Mycobacterium tuberculosis infection
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Pathogen-directed drug targets for tuberculosis therapy 
 
Minor groove binders and non-ionic surfactant vesicles 
delivery systems as anti-TB therapy 
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Chapter 2 Published Manuscript 
 
Evaluation of Minor Groove Binders (MGBs) as novel anti-
mycobacterial agents, and the effect of using non-ionic surfactant 
vesicles as a delivery system to improve their efficacy. 
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Summary  
 
In this chapter of the thesis, we screened the anti-mycobacterial activity of 172 minor 
groove binder (MGB) compounds that selectively bind to AT-rich regions of the minor 
groove of bacterial DNA with the helical structure matching that of DNA in Mtb culture.  
Of the 172 total compounds screened 17 hits were identified, of which 2, MGB 362 and 
MGB 364 displayed intracellular mycobactericidal activity against Mtb HN878 at an 
MIC50 of 4.09 and 4.19 M, respectively, whilst being non-toxic. Encapsulation of MGBs 
into non-ionic surfactant vesicles (NIVs) demonstrated a 1.6- and 2.1-fold increased 
intracellular mycobacterial activity, similar to that of rifampicin when compared with MGB 
alone formulation. The work presented in this chapter was published in the Journal of 
Antimicrobial Chemotherapy (Hlaka L, Rosslee MJ, Ozturk M, Kumar S, Parihar SP, 
Brombacher F, Khalaf AI, Carter KC, Scott FJ, Suckling CJ, Guler R. Evaluation of minor 
groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-
ionic surfactant vesicles as a delivery system to improve their efficacy. The Journal of 
Antimicrobial Chemotherapy. 2017;72:3334-41). The PhD candidate shared first co-
authorship in this publication. She performed all initial H37Rv-GFP optimization drug 
screening experiments with Dr Santosh Kumar. She performed all the H37Rv-GFP drug 
screening experiments presented in Figure 2.1  and Table 1.1 with Mr Michael Rosslee. 
The PhD candidate also performed the intracellular antimycobacterial screening and cell 
viability experiments in bone-marrow derived macrophages  presented in Figure 2.2 with 
Mr Michael Rosslee and Dr Suraj Parihar. She assisted Mr Rosslee, Dr Ozturk and 
A/Prof Guler in analyzing the MGB-NIV encapsulation for improved drug efficacy 
experiments presented in Figure 2.3. 
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2.1 Abstract 
 
Objectives: The slow development of major advances in drug discovery for the 
treatment of Mycobacterium tuberculosis (Mtb) infection have led to a compelling need 
for evaluation of more effective drug therapies against tuberculosis. New classes of 
drugs are constantly being evaluated for anti-mycobacterial activity with currently a 
very limited number of new drugs approved for TB treatment. Minor Groove Binders 
(MGBs) have previously revealed promising anti-microbial activity against various 
infectious agents; however have not yet been screened against Mtb. 
Methods: Mycobactericidal activity of 96 MGB compounds against Mtb was 
determined using H37Rv-GFP microplate assay. MGB hits were screened for their 
intracellular mycobactericidal efficacy against clinical Beijing Mtb strain HN878 in 
bone marrow- derived macrophages using standard colony-forming unit counting. Cell 
viability was assessed by CellTiter-Blue assays. Selected MGB were encapsulated 
into non-ionic surfactant vesicles (NIVs) for drug delivery system evaluation. 
Results: H37Rv-GFP screening yielded a hitlist of 7 compounds at an MIC99 between 
0.39 and 1.56 μM. MGB 362 and MGB 364 displayed intracellular mycobactericidal 
activity against Mtb HN878 at MIC50 of 4.09 μM and 4.19 μM respectively, whilst being 
non-toxic. Subsequent encapsulation into NIVs demonstrated a 1.6 and 2.1-fold 
increased intracellular anti-mycobacterial activity, similar to that of rifampicin when 
compared to MGB alone formulation. 
Conclusions: MGBs anti-mycobacterial activities together with non-toxic properties 
indicate that MGB compounds constitute an important new class of drug/chemical 
entity, which holds promise in future anti-TB therapy. Furthermore, NIVs ability to 
better deliver entrapped MGB compounds to an intracellular Mtb infection has 
provided merit for further preclinical evaluation. 
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2.2 Introduction 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), has become 
the top infectious killer worldwide. According to the 2016 World Health Organization 
(WHO) Global Tuberculosis Report [98], TB killed approximately 1.8 million people in 
2015, up from 1.5 million deaths in 2014 [99]. The current six-month treatment regimen 
for drug-susceptible Mtb, although still effective in most cases, is gradually becoming 
ineffective due to increasing resistance against the drugs used to treat TB [10]. Several 
advances have been made in the field of TB drug discovery, spearheaded by global 
partnerships. For example, the Global Alliance for TB Drug Development currently 
manages the largest array of novel anti-TB drug compounds and novel regimens for MDR 
and XDR TB[100]. Other initiatives to eradicate TB include the STOP TB partnership that 
includes an international working group to develop new TB drugs [9]. Furthermore, several 
large consortia of pharmaceutical companies (TB Drug Accelerator) and academia 
(MM4TB) drive the discovery of new TB drugs [101]. Despite the progress in the pipeline 
for new diagnostics, drugs, regimens, and vaccines, research remains relentlessly 
underfunded. As a consequence, only a few new drugs have been approved for clinical 
use, i.e. delamanid, bedaquiline and pretomanid, and only ten new drugs are in advanced 
phases of clinical trials as of 2016 [102, 103]. With the slow development of major 
advances in anti-mycobacterial drug discovery and the emergence of multi-drug-and 
extremely drug-resistant TB, there is an urgent need for the development of more effective 
therapies and formulations of existing drugs for the treatment of TB [11, 103]. In the area 
of novel therapeutics discovery, progress has been made in developing new drug classes 
such as benzothiazinones, which inhibit cell wall arabinan synthesis, and 
imidazopyridines, which inhibit respiratory chain ATP synthesis [104, 105]. Minor Groove 
Binder compounds (MGBs) have revealed promising antibacterial properties, but have not 
yet been investigated for their anti-mycobacterial activity against Mtb in vitro. 
 
Derived from the natural product distamycin, MGBs are a class of compounds that 
selectively bind to the minor groove of bacterial DNA with their helical structure matching 
that of DNA [106]. Most often, proteins binding to bacterial DNA bind to the major groove, 
leaving the minor groove exposed and thus, a vacant target for MGBs. Natural forms of 
MGBs are currently used in clinical treatment of disease. For example, aromatic 
diamidines, such as pentamidine [107, 108], and berenil [109], known to bind to the 
minor groove at adenosine-thymine tracts, have been administered clinically against 
human African trypanosomiasis and Pneumocystis carinii pneumonia [110-112]. MGBs 
display a wide variety of activity profiles against many infectious organisms evaluated, 
including Gram-positive bacteria [113], Mycobacterium aurum [114], chloroquine 
sensitive and 
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resistant Plasmodium falciparum [36], and Trypanosoma brucei brucei [111]. In 
partnership with MGB-Biopharma, one MGB compound has successfully completed 
phase I clinical trials for the treatment of Clostridium difficile infections [115]. We recently 
screened a limited number of MGBs for their anti-mycobacterial activity against the 
laboratory Mtb H37Rv strain with MIC99 reaching 3.1 uM [116]. We have now further 
extended this work by producing more active MGBs with higher MIC99 values against Mtb 
H37Rv. In addition, we examined the anti-mycobacterial activity of MGBs against 
intracellular clinical HN878 Beijing strain of Mtb and evaluated the effect of MGBs 
exposure on cell viability in macrophages. 
 
Oral drug administration has various limitations such as drug inefficiency resulting from 
drug insolubility caused by gastric low pH or poor absorbance in the gastrointestinal tract. 
However, an effective drug delivery system can improve drug retention at the site of 
infection. Therefore, an ability to deliver the drug to the site of infection may provide a 
sustained drug concentration enabling increased effectiveness of a drug against its target. 
In the case of pulmonary TB treatment, oral drug administration leads to high systemic 
concentrations of the drugs with associated side effects such as liver toxicity and 
cytotoxicity, amongst others [117]. Ultimately, the drawbacks associated with the oral 
administration of antibiotics laid the foundation for the development of innovative drug 
delivery approaches. The use of liposomes as a drug delivery system has been previously 
reported to reduce microbial drug resistance through faster drug delivery and increasing 
the antimicrobial drug concentration thereby preventing microbial drug efflux pump activity 
[118]. Liposome encapsulated drugs kill microbes faster before microbial mutations can 
develop. For example the incorporation of the antibiotic levofloxacin into liposomes 
improved the anti-mycobacterial activity to kill Mtb strain resistant to levofloxacin [119]. 
Other drug delivery systems such as non-ionic surfactant vesicles (NIV) have the ability 
to encapsulate both hydrophobic and hydrophilic drugs for direct delivery to the site of 
infection [52]. NIVs are small colloidal particles made of a non-aqueous, non-ionic 
surfactant bilayer that surrounds a central aqueous compartment. They are 
thermodynamically stable, easily manufactured and do not require special storage 
conditions. One of the major advantages of NIVs is that they are able to entrap different 
types of drug substances and can have their size altered. Their capacity to improve the 
delivery of small molecules is an important trait that allows for precise targeting of 
deposition of particles within the respiratory tract. Previous studies have shown NIVs to 
be a promising inhalable drug delivery system against pulmonary aspergillosis with 
aerosolized amphotericin B (AMB)-NIV administration reducing fungal lung burden when 
compared to AMB solution only [54]. More recent studies are showing antibacterial 
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action of moxiflacin [120] and cefixime [121] and antiviral action of nevirapine [122] in 
NIV formulations. Although many different drug delivery systems have been utilised to 
entrap first-line TB drugs, [123] only a few have systematically explored their anti-
mycobacterial activity against Mtb and against intracellular Mtb in infected primary 
macrophages. Thus, we have investigated the use of NIVs as a drug delivery system on 
the improvement of delivery and efficacy of novel MGB compounds to Mtb-infected 
macrophages. 
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2.3 Materials and methods 
 
2.3.1 Minor Groove Binder compounds 
MGB compounds were synthesized using distamycin template, a natural product with 
known infective properties as previously reported [25, 111, 116]. Alterations of the head, 
tail, side chains and body resulted in a number of diverse compounds with later synthesis 
driven by acquired screening data (Table S1). MGBs were re-suspended in DMSO to a 
concentration of 1.25 mM and were stored at -80˚C. 
 
2.3.2 Preparation of compounds and non-ionic surfactant vesicles 
MGB compounds (Stock: 1.25 mM) and rifampicin (Stock: 20 mM) were diluted to a 
starting concentration of 50 μM followed by 2-fold dilutions in 7H9 broth medium or DMEM 
to yield required screening range. Freeze dried NIVs were prepared as previously 
described [28] and rehydrated in DMEM + 10% FCS (Gibco, Thermofisher Scientific, 
USA) to a NIV concentration range of 23-5000 μM (empty NIV) and subsequently added 
to bone marrow-derived macrophages (BMDMs) in order to assess cell viability through 
CellTiter- Blue (Promega, Wisconsin, USA) assay with fluorescence detection at 
(544ex/590em nm). Subsequently, drug-NIV solutions were prepared in DMEM + 10% 
FCS at 2:5 molar ratio (MGB: NIV) at compound two-fold serial dilution range from 1.56 
to 12.5 μM (3.91-31.25 μM NIV) to assess cell viability and intracellular anti-mycobacterial 
activity. Two-fold serial drug dilution was performed as previously reported in other drug 
screening studies [124]. 
 
2.3.3 H37Rv-GFP microplate screening assay 
MGB compounds were screened for their anti-mycobacterial activity using 96-well, black 
clear flat-bottom microplates (Greiner Bio-One, Germany) as previously reported.[125, 
126] Single cell suspension of H37Rv-GFP from frozen stock with working concentration 
of 1x106 cfu/mL, was prepared in Middlebrook 7H9 supplemented with 25 mg/l kanamycin, 
10% Middlebrook OADC (v/v) and 0.05% tween 80 (w/v). The H37Rv-GFP Mtb strain 
was a donation from Ernst lab in New York University School of Medicine, USA. 100 μL 
of H37Rv-GFP at a concentration of 1x105 cfu/well was added to each experimental well. 
100 μL of drug compounds prepared in 7H9 broth supplemented with 25 mg/L 
kanamycin to generate 0.195-50 μM screening range, was added to well containing 
H37Rv-GFP for final screening range of 0.0977-25 μM. Wells containing compound only 
at the highest screening concentration were used to detect autofluorescence of 
compounds and broth (vehicle control). Fluorescence (485ex /520em nm) was measured 
at designated time points; days 0, 4, 8, 10 and 12 with BMG Labtech Omega Plate 
Reader (Germany). The addition of sterile water to the outer wells of each plate served to 
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minimize the evaporation. Time intervals were selected as previously reported in other 
drug screening studies [126]. 
 
2.3.4 Bone marrow-derived macrophages generation and Mtb infection 
 
BMDMs were generated from 8-12 week old C57BL/6 mice as previously reported [127]. 
After differentiation, BMDMs were plated into 96-well plates (Nunc, Denmark) at 2 x 105 
cells per well. Following overnight adherence, BMDMs were then infected with Mtb 
HN878 (MOI=5) and cultured at 37˚C under 5% CO2 for 4 hours. BMDMs were washed 
once with pre-warmed culture media to remove extracellular bacteria or lysed and 
lysates plated on 7H10 agar plates supplemented with 10% OADC and 0.5% glycerol for 
cfu counting to determine bacilli uptake. Drug compounds prepared in DMEM media 
supplemented with 10% FCS at defined concentrations were added to infected BMDMs 
to determine anti- mycobacterial activity and cell viability using rifampicin no treatment 
(no-drug) groups as controls. After 5 days of culture, cells were lysed for cfu plating or 
assessed for cell viability by CellTiter-Blue assay. 
 
2.3.5 Statistical analysis 
All data were analysed using R, a student t-test (two-tailed with equal variance) or unless 
otherwise stated in figure legends. A *p value of less 0.05 was considered significant, 
with **p < 0.01 and ***p < 0.001
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2.4 Results 
 
2.4.1 Minimum inhibitory concentration (MIC99) of MGB compounds against H37Rv- 
GFP 
 
We screened 96 MGBs for their anti-mycobacterial activity against GFP-labelled H37Rv 
Mtb in liquid broth culture using a 96-well plate assay (Table 1). Relative fluorescence was 
measured at 0, 4, 8, 10 and 12 days in broth culture of MGBs (serially diluted from 25 µM 
to 0.19 μM) to determine the minimum inhibitory concentration (MIC99) of MGBs required 
to eradicate 99% of Mtb (Figure 2.1). Hit compounds, defined as previously reported 
[128], were identified as drugs that were active at or below the threshold concentration of 
3.12 μM. A hitlist of 7 compounds were identified with an MIC99 of 1.56 μM or less 
(Figure 2.1 and Table 1). Rifampicin, which had an MIC of 0.0977 μM, was used as the 
positive control. The selected hit compounds were MGBs 362, 368, 361, 365, 359, 364 
and 367 with MIC99 range (0.391-1.56 μM) and therefore were identified for subsequent 
intracellular anti-mycobactericidal activity screening. 
 
2.4.2 Intracellular drug activity against clinical Mtb and macrophage cell viability 
The ability of anti-TB drug compounds to penetrate macrophages and induce 
mycobactericidal activity, while being non-toxic to the macrophages, is a salient property 
sought after in TB drug development. Hence, BMDMs were exposed to serial MGB drug 
concentrations from 1.56 to 12.5 μM to evaluate their anti-mycobacterial activity against 
the clinical Mtb strain HN878, after 5 days of infection. Compounds were screened for the 
concentration which eradicated 50% of bacilli (MIC50, Figure 2.2A). Two of the 7 hit 
compounds identified from screening studies against Mtb in Figure 1 had good 
intracellular mycobacterial killing efficacy against Mtb-infected macrophages, with MIC50 
values of 4.09 μM (MGB 362) and 4.19 μM (MGB 364). Rifampicin, selected as a positive 
control, had a MIC50 of 1.7 μM. CellTiter-Blue cell viability assay was performed to assess 
for macrophage cell viability in MGBs-treated BMDMs after 5 days of exposure (Figure 
2.2B). MGB 362 and 364 and rifampicin had no significant effect on macrophage viability 
at the respective intracellular drug activity MIC50 concentrations (Figure 2.2B). These 
data suggest that MGB 362 and 364 have an efficient intracellular anti-mycobacterial 
activity against Mtb while being non-toxic to the host cells. 
 
2.4.3 MBGs-NIV encapsulation increased intracellular drug activity against clinical 
strain of Mtb 
 
We next investigated whether encapsulating our hit MGB compounds into NIVs, a drug 
delivery system that was previously reported to improve drug delivery of amphotericin B 
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to macrophages,[54] would improve MGBs drug efficacy against the intracellular clinical 
HN878 Mtb strain. We demonstrated that encapsulating MGBs into NIVs improved the 
intracellular anti-mycobacterial abilities by 2.1-fold for MGB 362, and 1.6-fold for MGB 364 
in Mtb HN878-infected BMDMs, displaying a significant cfu reduction (P < 0.01) compared 
to controls (Figure 2.3A). The anti-mycobacterial killing activity of MGB 362-NIV and 
MGB 364-NIV were similar to that of rifampicin. MGB 364 displayed a significant 
decreased cfu counts (P < 0.033) when compared to MGB alone. Furthermore, Mtb-
infected macrophages were viable following MGB-NIV treatment (Figure 2.3B). 
Treatment with NIV- alone also had no significant effect on macrophage viability (data 
not shown). These results demonstrate that NIVs can act as a suitable delivery system 
by transporting MGB inside macrophages, the target cells for Mtb. 
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2.5 Discussion 
MGB compounds have shown great potential for their use as antibacterial therapeutic 
agents [25]. However, their activity against Mtb remains unknown. Here, we demonstrated 
the anti-mycobacterial (MIC99) properties of MGBs against Mtb (H37Rv-GFP) with a 
reliable screening method that enables the detection of most active compounds,[129] 
using rifampicin as a positive control (Table 1, Figure. 2.1). All of the active MGB 
compounds belong to the well- established alkene-linked minor groove binder family 
discovered at the University of Strathclyde with high killing activities against different 
pathogens as previously reported [17,19-21, 23, 33]. Since the primary binding sites of all 
of these MGBs in the DNA minor groove are AT rich regions it is unlikely that target 
sequence specificity is responsible for the selectivity observed. This is true also for the 
active compounds against Mtb described here. However, it is more likely that activity and 
selectivity against a particular pathogen is caused by differential access to cells caused 
by differing cell wall and cell membrane structures in a way that with the current state of 
knowledge is idiosyncratic and unpredictable [25]. What can be reliably stated is that the 
alkene-linked compounds are significantly the most biologically active of the Strathclyde 
MGB family. In general, MGBs with the most significant antibacterial activity possess a 
range of different tail groups, all of which are exemplified within the set in our screen. 
However, all of the most active MGBs identified in this study possess an amidine-
containing tail group, which perhaps suggests an important role of tail group pKa for 
targeting mycobacteria. 
 
Screening of MGB compounds in the context of their cell viability and anti-mycobacterial 
activity against intracellular clinical Mtb strain HN878 have identified two compounds with 
promising results, giving a hit rate of 2.1% (2/96) (Figure.2. 2). In most studies the hit 
rate for hit compounds is in the order of 1%, in-line with previous studies.[130] These 
findings however warrant in vivo testing which aims to allow for better clinical therapeutic 
translation of the findings. The use of non-ionic surfactant vesicles (NIVs) has been 
demonstrated repeatedly in literature before and constitutes a prominent focus within 
current Mtb research in order to combat the infection [52, 131]. NIVs given by nebulisation 
delivered amphotericin B to the lungs and liver with significantly improved treatment 
outcome when compared to AMB solution against pulmonary aspergillosis and visceral 
leishmaniasis [28]. Our investigation of NIVs as a delivery device indeed demonstrate that 
NIVs can be used to enhance the efficacy of MGB compounds against HN878 in infected 
BMDMs whilst not increasing the toxicity of the drug to BMDMs. MGB contain hydrophobic 
head groups (Figure. 2.3) [106] which allows for encapsulation into NIV. Liposomes have 
previously been reported to encapsulate an alkyl derivative of distamycin A [132] which 
are naturally occurring backbones for MGB compound synthesis. 
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NIVs ability to trap the drug within its hydrophilic/-phobic compartment allows the drug to 
be taken up by phagocytosis by the infected macrophage, thereby transporting the drug 
to the site of infection. Using NIV drug formulations resulted in higher drug levels 
compared to similar treatment with drug solution at the site of infection after treatment by 
the pulmonary or intravenous routes for water soluble [133, 134] and lipid soluble drugs 
[54]. Studies in dogs treated by the intravenous route with a sodium stibogluconate- 
dextran (SSG)-NIV formulation increased the elimination half-life and the volume of 
distribution at steady state compared to SSG-dextran solution [135]. Therefore NIV-MGB 
formulation can be a feasible pulmonary treatment for Mtb. 
 
In conclusion, this study showed that MGBs constitute an important new class of 
drug/chemical entity with favourable anti-mycobacterial activity and holds promise in 
future anti-TB therapy. Furthermore, we demonstrate that NIVs contribute to better 
delivery of drugs to an intracellular infection and secondly act as a delivery device for 
entrapped MGB compounds and lastly serve as the initial step into future research of 
targeted delivery of entrapped drug to Mtb-infected cells. 
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Table 2.1. MIC99 of all screened MGBs against H37Rv-GFP. 7 hits were identified 
out of 96 MGBs screened. MGBs marked with asterisk symbols were previously 
screened as reported. [77]. 
 
 
Compound MIC99 Compound MIC99 Compound MIC99 
 
Rifampicin 0.0977 371 25 235 >25 
362 0.391 372 25 245 >25 
368 0.391 373 25 246 >25 
361 0.781 374 25 247 >25 
365 0.781 381 25 248 >25 
359 1.56 1 >25 270 >25 
364 1.56 2 >25 271 >25 
367 1.56 9 >25 283 >25 
353* 3.12 12 >25 286 >25 
354* 3.12 74* >25 287 >25 
391 3.12 85 >25 288 >25 
263 6.25 92 >25 289 >25 
343 6.25 114 >25 300 >25 
385 6.25 121 >25 303 >25 
386 6.25 122 >25 304 >25 
351* 12.5 123 >25 305 >25 
352* 12.5 124 >25 306 >25 
376 12.5 131 >25 322 >25 
377 12.5 134 >25 323 >25 
H
it
s 
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378 12.5 147 >25 324* >25 
379 12.5 154 >25 325 >25 
380 12.5 176 >25 329* >25 
383 12.5 185 >25 331* >25 
387 12.5 187 >25 332* >25 
390 12.5 188 >25 333* >25 
282 12.5 - 25 192 >25 334* >25 
4* 25 210 >25 335* >25 
116 25 212 >25 336* >25 
164 25 213 >25 338* >25 
292 25 214 >25 356 >25 
317* 25 222 >25 357 >25 
330* 25 234 >25 358 >25 
337 25     
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Figure 2.1: Screening of anti-mycobacterial activity of MGB compounds against H37Rv-
GFP. Direct antimicrobial activity of MGB compounds at the drug concentration range of 0.195 – 
25 μM was tested against H37Rv-GFP (1x105 cfu/well) in 7H9 liquid broth culture using microplate 
assay. The anti-mycobacterial activity of MGB treatment on H37Rv-GFP was determined at a 
concentration-dependent manner by measuring fluorescence (485ex/520em nm) on days 0, 4, 8, 10 
and 12. Data was corrected for background 7H9 fluorescence. Data show mean ± SEM of 
duplicates. 
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Figure 2.2: MIC50 of MGB compounds in HN878 Mtb-infected BMDMs and cell viability. A) 
The intracellular anti-mycobacterial activities of MGBs (1.5625-12.5 μM) and rifampicin (0.3906-
3.125 μM) were assessed by counting cfu at the respective concentration at 5 days post Mtb 
HN878 infection. MIC50 values of each drug compound were identified in GraphPad Prism by non-
linear regression analysis. B) Macrophage cell viability was determined at 5 days of MGB 
compound exposure and measured by CellTiter-Blue assay with fluorescence detection at 
(544ex/590em nm). Data were corrected for background culture medium fluorescence and are 
shown mean ± SEM, representative of triplicates. Two-tailed Student’s t-test, *p < 0.05, **p < 
0.01, *** p < 0.001 compared to no-drug control. 
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Figure 2.3: MGBs-NIV formulation intracellular mycobacterial activity in HN878 Mtb-
infected BMDMs and cell viability. A) The intracellular anti-mycobacterial activity of MGBs only, 
MGBs- NIV formulation and rifampicin was determined in comparison to control (no drug 
treatment). Cfu was determined at 5 days post Mtb HN878 infection. B) Macrophage cell viability 
was determined at 5 days post Mtb HN878 infection and measured by CellTiter-Blue assay with 
fluorescence detection at (544ex/590em nm). Data were corrected for background culture media 
fluorescence and are shown as show mean ± SD, representative of triplicates. Two-tailed 
Student’s t-test, *p < 0.05, ** p < 0.01, *** p < 0.001 compared to no-drug control. 
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Chapter 3 Manuscript in preparation 
 
Evaluation of in vivo antimycobacterial activity of MGB and NIV 
encapsulation via intranasal administration
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            Summary  
 
In this chapter we  assessed the in vitro genotoxicity of our lead compound MGB 364 
and MGB-NIV 364 in murine bone marrow-derived macrophages infected with clinical 
Beijing Mtb strain HN878. Detection of γ-H2Ax by flow cytometry was used as a 
biomarker for DNA double-strand damage. We next investigated the in vivo activity of 
MGB 362, MGB 364 compounds and the use of NIV as an effective delivery system in 
vivo. Here we found that treatment with MGB 364 or MGB-NIV 364 formulation did not 
cause DNA damage as displayed by low detection of γ-H2Ax compared to H2O2 and 
DMSO treated groups. MGB 364 at low concentrations was effective in killing Mtb in 
vivo. The use of NIVs improved the activity of these compounds. From these studies we 
could conclude on the potential of MGB 364 as a lead compound against Mtb infection. 
Interestingly we also observed that intranasal administration of MGB-NIV 364 
formulation improved immune responses and pathology during Mtb infection. With this 
we could conclude on the possibility of an adjunct TB therapy while using NIVs. In this 
case NIVs would be effective in delivering the drug of interest as well as trigger immune  
activation necessary for killing of the pathogen. The PhD candidate performed all 
genotoxicity experiments shown in Figure 3.1. She performed Mtb infections with Dr 
Mumin Ozturk, treatment experiments by herself; lung homogenates, bacterial burden 
and lung weight experiments with Dr Mumin Ozturk, Mr Julius Chia and Mr  Nathan 
Kieswetter presented in Figure 3.2. She performed immunohistochemistry in Figures 3.3- 
3.6; ELISA in Figure 3.7 and flow cytometry experiments in Figure 3.8 by herself.  
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3.1 Abstract 
 
Objectives: Our Strathclyde Minor Groove Binders (S-MGBs) have previously shown 
promising intracellular anti-mycobacterial activity against Mtb whilst showing modest 
cytotoxicity to host cells. However, they have not been investigated for in vivo efficacy. 
Furthermore, their ability to potentially cause genotoxicity had not yet been investigated. 
Methods: Genotoxicity was assessed in murine bone marrow-derived macrophages 
infected with clinical Beijing Mtb strain HN878. Expression of γ-H2Ax by flow cytometry 
was used as a biomarker for DNA double-strand damage. In vivo efficacy of MGBs, 
rifampicin and MGB-NIV formulation against pulmonary Mtb infection was measured in 
C57BL/6 mice through intranasal administrations once per week for 3 weeks. Four weeks 
post-infection, lungs and spleens were collected from euthanized mice to determine 
immunohistopathology, lung inflammatory cell infiltration and bacterial loads using 
standard colony-forming unit assay. 
Results: Treatment with MGB 364 or MGB-NIV 364 formulation did not cause DNA 
damage as displayed by low detection of γ-H2Ax compared to H2O2 and DMSO treted 
groups. Intranasal administration of 0.5mg/kg MGB 364 or (0.5mg/kg: 30mM) MGB-NIV 
364 formulation showed one log reduction in bacterial burden with improved pathology 
and cytokine production of IL-1α, IL-17 and IFN-γ when in NIV formulation. However, 10 
mg/kg MGB 362 or rifampicin had no effect on bacterial loads. 
Conclusions: Our MGB compounds had limited DNA damage to host cells. Intranasal 
administration of MGB 364 was effective directly at site of infection. Encapsulation of 
MGBs into NIV improved efficacy through immunomodulatory properties suggesting a 
potential for intranasal treatment with MGBs as an effective route of administration for 
pulmonary Mtb infection. Thus, showing a potential for an effective anti-TB drug 
formulation for TB therapy when using NIVs as a delivery system. 
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3.2 Introduction 
Minor groove binders (MGB)s have shown great potential as antibacterial agents. We 
previously reported on the anti-mycobacterial properties of various MGBs against 
Mycobacterium tuberculosis (Mtb) [29, 136]. The activity was attributed to specific 
changes in the structural composition of these compounds in respect to cell wall 
penetration properties. The inclusion of a thiazole head group in replacement of the 
pyrrole unit increased lipophilicity and DNA binding which provided the anti-infective 
activity of first set of MGBs screened [29]. Similar activities of MGB classes containing 
different head groups was attributed to the similar amidine-containing tail groups which 
promoted selectivity to the pathogen [136]. We showed that our selected MGB 
compounds, MGB 362 and MGB 364 had intracellular activity against Mtb. We further 
showed that encapsulating these MGBs into non-ionic surfactant vesicles improved the 
intracellular activity of these compounds whilst showing modest mammalian cell toxicity 
through an approach that measures mitochondrial activity and cellular metabolism [136]. 
 
DNA intercalating agents that bind to DNA both covalently and non-covalently have been 
shown to cause mutagenic shifts especially in bacteriophages and bacterial assays. 
However, they have shown weak genotoxic and mutagenic activities in mammalian cells 
[137]. In a study of mutagenicity of N-acyloxy-N-alkoxyamides in S. typhimurium TA100, 
N-acetoxy-N-butoxynaphthamide binding resulted in an increased log P value which 
indicated an increased level of mutagenicity and this was ascribed to DNA intercalating 
binding rather than hydrophobic binding in the major and minor groove of DNA [138]. The 
genotoxicity effect of tamoxifen in Chinese hamster V79 cells was a consequence of the 
formation of covalent adducts with DNA which was attributed to DNA intercalation [139]. 
Non-covalent bonding which is facilitated by hydrogen bonds and van der Waals forces 
occurs mainly at the major and minor groove of DNA or through the intercalation of a 
molecule between base pairs. Minor groove binders such as mitomycins or distamycins 
are generally non-genotoxic unless covalent bonding of an adjacent molecule or the 
formation of free radical-dependent DNA double-strand breaks is enabled [140]. 
Distamycin and diamidine-2-phenylindole (DAPI) were reported to confer chemoprotective 
activity through the catalytic inhibition of DNA topoisomerase (topo II) which would 
otherwise facilitate cytotoxicity and the formation of DNA double-strand breaks [141, 142]. 
Phosphorylation of histone H2Ax occurs during of DNA damage responses (DDR) that 
are activated due to DNA double-strand breaks [143]. The phosphorylated form γ-H2Ax 
accumulates at the site of the damage and can be used an indicator of both the number 
and location of these breaks in the nucleus [143-145]. Here we investigated the ability of 
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MGB 364 or the encapsulated formulation MGB-NIV 364 to cause genotoxicity using the 
detection of γ-H2Ax as a biomarker for genotoxic exposure. 
 
Pulmonary administration of TB drug formulations or vaccines by inhalation have shown 
to be more effective during drug efficacy screening against pulmonary TB. This has shown 
to increase drug concentration, bioavailability and sustained release pattern at the site of 
infection [42, 146, 147]. Lipid nanoparticle delivery systems improved lung delivery of 
poorly soluble molecules like rifampicin [42, 146, 148, 149]. Single dose administration of 
RIF in freeze-dried liposome formulation in Wister rats via the pulmonary intratracheal or 
oral routes showed prolonged plasma retention of RIF compared to free drug administered 
[146]. In the study, RIF was detected from 4 hrs up to 48 hrs when administered in 
formulation, while free drug was cleared from circulation within 24 hrs [146]. 
Pharmacokinetic analyses thus showed that RIF in encapsulation with liposome upon 
pulmonary administration resulted in increased relative bioavailability compared to free 
drug [146]. To evaluate the chemotherapeutic potential of solid lipid nanoparticles (SLPs) 
via the respiratory route in guinea pigs, the researchers incorporated three frontline anti- 
TB drugs (RIF, INH and PZA) in formulation with SLPs [148]. Therapeutic drug 
concentrations of all three drugs were detected from 45 mins and maintained in the 
plasma for 5 days and 7 days in lungs, liver and spleen, whereas free drugs were only 
maintained for 1 or 2 days. Drug bioavailability improved by 8-10 folds in the case of drug- 
loaded SLPs similarly to Mtb-infected guinea pigs. After 7 weekly (7th day) doses of 
nebulization treatment of drug-loaded SLPs to infected guinea pigs, no tubercle bacilli 
were detected in lungs or spleen which was equivalent to 46 daily doses of orally 
administered drugs to obtain similar therapeutic effect. Furthermore, there was no 
biochemical hepatotoxicity observed [148]. Pulmonary administration of the second-line 
TB drug ethionamide when co-encapsulated with its booster BDM41906 into 
biodegradable polymeric nanoparticles resulted in a 3-log decrease in pulmonary bacterial 
loads after 6 administrations [150]. Thus, showing the importance of drug delivery 
systems in the treatment of pulmonary tuberculosis. We therefore tested the in vivo 
efficacy of MGB 362, MGB 364 and MGB-NIV 364 formulation in mice models during 
pulmonary infection with hypervirulent Mtb strain HN878 via intranasal route of 
administration using rifampicin as control 
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3.3 Materials and Methods 
 
3.3.1 Mice 
Female wildtype C57BL/6 mice aged between 8-12 weeks old were used. Mice were 
divided into n=3-6 animals per group for each experiment and kept under pathogen-
free conditions in individually ventilated cages at the University of Cape Town Animal 
Facility unit Biosafety level 2 (BSL-2) or BSL-3 laboratory for Mtb-infected mice. Animal 
room temperature was maintained at 22-25 ˚C and 12 hours light/dark cycle. Food 
pellets and water were made available ad libitum. 
 
3.3.2 Ethical statement 
All experimental procedures were carried strictly in accordance with the South African 
National Standard (SANS 10386:2008) and the University of Cape Town’s ethical 
committee guidelines under protocol numbers (015/036 and 015/037). All treatments 
and infections were performed under intraperitoneal injection (IP) of 10mg/kg xylazine 
and 100mg/kg ketamine anaesthesia. All euthanasia was performed under halothane 
to minimize suffering of mice. 
 
3.3.3 Preparation of Minor groove binder compounds and non-ionic surfactant 
vesicles 
 
Minor groove binder compounds 362 or 364 or 10 mg/kg rifampicin were dissolved in 
1x PBS/saline or diluted in DMEM to yield a concentration 10mg/kg (MGB 362) or 
0.5mg/kg (MGB 364) per mouse or 10 µM in macrophages. Freeze dried NIVs were 
prepared as previously described [54] and rehydrated in PBS/saline or DMEM + 10% 
FCS (Gibco, Thermofisher Scientific, USA) to a final NIV concentration range of 30μM 
in formulation with MGBs or empty NIV. 
 
3.3.4 Generation of murine bone marrow-derived macrophages and Mtb infection 
BMDMs were generated from 8-12 weeks old C57BL/6 mice as described [127]. 
Following 10 days of differentiation, BMDMs were cultured in triplicates overnight for 
adherence into 96-well plates (Nunc, Denmark) at 5 x 104 cells per well. Single cell 
suspension of hypervirulent HN878 Mycobacterium tuberculosis (Mtb) from frozen stock 
was prepared in DMEM media. After 24hr adherence, BMDMs were infected with HN878- 
Mtb at MOI 1:5 CFU per well. At 4hrs post-infection, BMDMs were then washed once with 
culture media to remove extracellular bacteria or lysed. Lysates were plated on 7H10 agar 
plates containing 10% OADC and 0.5% glycerol for CFU counting to determine bacilli 
uptake.
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                     3.3.5 Evaluation of MGB induced genotoxicity 
After 24hr post-infection, MGB 364, MGB-NIV 364, rifampicin and toxicity inducing agents, 
hydrogen peroxide (H2O2) and dimethyl sulfoxide (DMSO) were prepared in DMEM media 
supplemented with 10% fecal calf serum (FCS) at defined concentrations of 10µM and 
added to infected BMDMs. After 4 and 24 post-treatment, cells were harvested and 
assessed for genotoxicity by flow cytometry by the following antibodies: CD11b 
(PercCPcy-5.5); mouse/human anti-phospho histone SER-139 H2Ax (H5912) and isotype 
control (Alexa fluor 488); F/480 (Alexa fluor 647); MHCII-(Alexa fluor 700); polyclonal 
rabbit anti-histone H2A.X (AB10022), goat anti-rabbit IGg (Alexa flour 488) secondary 
antibody. For staining of surface markers, cells were washed in 1x PBS and labelled with 
respective markers and then washed in FACS buffer (1X PBS with 1% BSA and 0.1% 
NaN3). Intranuclear expression of γH2Ax was detected using BD Pharmingen 
Transcription Factor Buffer Set (BD Biosciences) according to manufacturer's instruction. 
Acquisition was conducted using BD LSR Fortessa and data analysis was performed with 
FlowJo software (Treestar, Ashland, OR, US). 
 
3.3.6 In vivo Mtb infection and intranasal MGB/ MGB-NIV treatment in mice 
 
Mice were infected with HN878-Mtb strain at 100 or 1000 CFU per mouse via intranasal 
route as described [17]. After 7 days post-infection, mice were anaesthetized with an IP 
injection of 10mg/kg xylazine and 100mg/kg ketamine and treated once per week for 21 
days with 10mg/kg of MGB 362 or 0.5 mg/kg of MGB 364 or 0.5mg/kg: 30mM MGB- NIV 
364 formulation. 10mg/kg rifampicin was used as a positive control, while saline and no 
treatment were used as negative controls. Mice were monitored daily and weighed once 
weekly and euthanized with halothane when animals lost 20 % of their original body weight 
or showed any signs of distress such as lack of grooming, coat staring, hunched up 
posture, open mouth breathing, difficulty in breathing and immobility. At the end of the 
study, mice were euthanized to assess drug treatment efficacy. Lungs and spleens were 
isolated to determine bacterial load using CFU assays. Infiltration of inflammatory cells 
were also determined from single cell suspensions of lung tissues 3 weeks post-treatment 
by flow cytometry. 
 
3.3.7 Oral MGB treatment in mice 
After 7 days following infection with 100 CFU HN878, mice were treated once per week 
with 10 mg/kg MGB 362 control mice with 10 mg/kg rifampicin or with saline by oral gavage
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for 3 weeks. Four weeks post infection, mice were euthanized, lungs and spleens were 
isolated to determine bacterial loads using CFU assays. 
 
3.3.8 Preparation of tissue homogenates to determine bacterial load 
Following sacrifice, lungs and spleens were removed aseptically, weighed, and 
homogenized in 0.04% Tween-80 in saline solution. Homogenates were diluted into ten-
fold serial dilutions and plated onto Middlebrook 7H10 (BD Biosciences, San Jose, CA) 
agar plates containing 10% OADC and 0.5% glycerol and incubated at 37°C followed by 
colony counts after 21 days of incubation. 
 
3.3.9 Histopathological and Immunohistochemistry examination 
 
Formalin fixed (4%) Mtb-infected lungs from wild-type littermate controls and IL-4i1-/- 
mice were stained with hematoxylin and eosin or rabbit anti-mouse iNOS (Abcam) and 
detection performed using HRP-labelled anti-rabbit and anti-goat, respectively as 
described [80, 151]. Gelatine-based mounting medium was used to mount the sections. 
Image acquisition and quantification of alveolar airspaces, iNOS and Arg1 were 
performed using NIS advanced software on a Nikon (Tokyo, Japan) 90i microscope. 
Percentage of free alveolar airspaces was defines as the area of ventilated spaces in 
whole lung sections in relation to the total lung tissue area using the area measurement 
tool by NIS advanced software on a Nikon 90i microscope and % alveolar spaces 
calculated using Excel as described [21]. The percentage of iNOS and Arg1 was 
performed using a blinded quantification method as described [21].  
 
3.3.10 Flow Cytometry 
Single cell suspensions from lung tissues were stained for surface markers with the 
following antibodies: F4/80 (PE-Cy7) from Affymetrix eBiosciences; LY6C (PercCP- 
Cy5.5); CD11c (V450); MHCII (Alexa Fluor 700); CD103 (PE); CD11c (Alexa Fluor 647); 
SiglecF (APC-Cy7); CD44 (FITC); NK1.1 (APC-Cy7); CD62L (V450); TCR gamma delta 
(biotin); CD19 (PercCP-Cy5.5); CD8 (Alexa Fluor 647), Streptavidin (Texas Red), LY6G 
(FITC) and CD4 (PE) from BD Biosciences in FACS buffer. Acquisition was conducted 
using BD LSR Fortessa, and data analysis was performed with FlowJo software (Treestar, 
Ashland, OR, US). 
 
3.3.11 Cytokine responses 
Supernatants collected from lung homogenates were used to determine cytokine 
production using enzyme-linked immunosorbent assay. IL-6, IL-4, IL-12p40, TGF-β and 
IFN-γ (BD Biosciences); IL-1α, IL-1β (R&D Systems, Minneapolis, MN); TNF-α, IL-17, IL- 
10 (BioLegend) production was measured from the supernatants and data analysed using 
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SoftMax Pro 6. 
 
3.3.12 Statistical analysis 
All data were analysed using Graph-Pad Prism 6.0. Data were calculated as mean ± SEM. 
Statistical significance was calculated with one-way ANOVA was used. A *p value of less 
than 0.05 as considered significant, with **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
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3.4 Results 
 
3.4.1 MGB treatment is not genotoxic to murine and human macrophages as 
determined by Gamma-H2Ax expression 
Intranuclear expression of phosphorylated H2Ax was measured to detect drug induced 
DNA damage in HN878-Mtb infected CD11b+F/480+MHCII+ murine macrophages. Using 
isotype control as a point of reference, the expression of γ-H2Ax remained significantly 
low (p< 0.05) in MGB 364, MGB-NIV 364 and rifampicin compared to macrophages 
treated with H2O2 at 4-24 hrs post-treatment and DMSO 24 hrs post-treatment (Fig. 3.1). 
These data suggest that MGB or MGB-NIV compounds do not cause DNA damage to 
host cells. 
3.4.2 MGB-364 reduced bacterial load, NIV encapsulation improved drug efficacy 
of MGB-364 during acute Mtb infection in mice 
Next, we sought to determine the in vivo efficacy of MGB compounds by directly targeting 
the site of infection in mice intranasally infected with HN878-Mtb. We first investigated the 
in vivo efficacy of MGB 364 directed at the site of infection and whether encapsulating 
MGB 364 into NIVs, a drug delivery system that was previously reported to improve its 
efficacy in macrophages, would improve MGB 364 efficacy against HN878-Mtb strain in 
vivo [136]. Intranasal treatment with MGB 364 showed a significant one log reduction 
(p< 0.01) in lung bacterial loads 3 weeks post-treatment when compared to no treatment 
group (Figure 3.2A). However, similar bacterial loads were detected in the spleens, 
suggesting that MGB 364 was retained and more effective against Mtb directly at the site 
of infection (Figure 3.2B). We also treated infected mice with MGB-NIV 364 or empty 
NIV as controls. Intranasal treatment with MGB-NIV 364 showed a significant one log 
reduction (p < 0.01) in lung bacterial loads similarly to that of MGB 364 alone compared 
to the no treatment group (Figure 3.2A). Surprisingly, empty-NIV treatment had a similar 
reduction compared to no treatment group, suggesting that NIVs influenced the killing of 
Mtb in vivo (Figure 3.2A). A significant reduction in lung weight index was observed in 
mice treated with MGB 364, suggesting a reduced inflammation in the lung compared to 
the no treatment group (Figure 3.2C). To check in vivo efficacy of MGB-362, mice were 
intranasally treated with 10mg/kg of MGB 362 or 10mg/kg rifampicin or saline or left 
untreated. Bacterial loads were similar across the treatment groups at 3 weeks post-
treatment as determined by cfu counts in both lungs and spleens of infected mice 
(Figure 3.2D and 3.2E). These data suggest that MGB 362 does not reduce Mtb burden 
in vivo. Surprisingly, rifampicin also did not reduce the Mtb burden, suggesting that 
rifampicin intranasal administration was not effective for Mtb treatment in vivo (Figure 
3.2D). Similarly, there were no significant differences in lung weight 
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index across all groups (Figure 3.2F). We next changed the route of administration to 
oral administration by oral gavage to evaluate the efficacy of MGB 362 in vivo. Similarly 
oral administration of MGB 362 had no effect on bacterial loads and no effect on lung 
weights across groups were observed, but one log reduction in bacterial burden (p< 
0.05) was observed with RIF treatment (Figure 3.2. G-I). 
 
3.4.3 Rifampicin improved histopathology of HN878 Mtb-infected mice 
We next investigated the effect of MGB 364 or MGB-NIV 364 on the histopathology of 
infected mice through the quantification of lung alveolar airspaces. Treatment with MGB 
364 had no effect on the pathology of Mtb-infected mice, however treatment with MGB 
364-NIV and empty-NIV decreased disease pathology as shown by a significant increase 
in free alveolar airspaces compared to no treatment group (Figure 3.3A-B). MGB 362 
had no effect on the histopathology of infected mice with alveolar spaces similar to the 
no treatment and saline control groups (Figure 3.4A-B). Surprisingly, although no effect 
on bacterial loads, intranasal treatment with rifampicin improved the histopathology 
status of infected lungs as shown by a significant increase (p < 0.01) in alveolar 
airspaces compared to no treatment groups (Figure 3.4A-B). There was no significant 
difference on tissue iNOS and Arg1 expression in all groups (Figure 3.5A-D; Figure 
3.6A-D), suggesting that MGB and MGB-NIV treatment has does not induce iNOS and 
Arg1 tissue expression in Mtb-infected mice. 
 
3.4.4 NIV encapsulation of MGB 364 increased the production of IL-1α, IL-17 and 
IFN- γ while MGB 362 reduced IL-1β, IL-12p40 and IL-10 cytokine production, but 
increased CD4 T-cell recruitment following Mtb infection 
We next investigated the effect of MGB 364 and MGB-NIV 364 on immune responses, 
determined by cytokine production in the lungs. MGB-NIV 364 treatment showed a 
significant increase (p < 0.05) in pro-inflammatory cytokine IL-1α production, similarly to 
empty-NIV treatment. Furthermore, IFN-γ and IL-17 were significantly increased (p < 0.01 
and p < 0.05 respectively) in MGB-NIV 364 treated groups, but had no effect on other 
cytokines measured (Figure 3.7A-B). These data thus suggest that the NIV 
encapsulation improved effector cytokine production which correlates to improved 
immunopathology of disease outcome. Interestingly, a significant reduction (p < 0.01) in 
pro-inflammatory IL- 1β, IL-12p40 and regulatory IL-10 cytokines was observed in MGB 
362 treated group compared to no treatment group (Figure 3.7C), suggesting that MGB 
362 had reduced effect on pro-inflammatory effector responses during Mtb infection. 
Similarly, MGB 364 treatment alone had similar levels of cytokine production when 
compared to the no treatment group (Figure 3.7A-B). We measured the effects of 
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MGB 362 and rifampicin on cellular infiltration in the lungs by flow cytometry in Mtb-
infected mice. Mice treated with MGB 362 showed significant increase (p < 0.001) in 
CD4+ T-cell population compared to control groups. However, rifampicin treatment 
showed a significant increase in CD11b+ MHCII+ CD11chigh monocyte-derived dendritic 
cells (mDCs) (Figure 3.8A-B). 
 
3.5 Discussion 
We previously reported on the intracellular antimycobacterial properties of MGB 362 and 
MGB 364 and the use of NIV’s to improve their efficacy whilst being non-toxic [136]. The 
activity of the MGBs was attributed to the amidine-containing tail group and the 
permeability to different cells types. However, the ability of these compounds to cause 
DNA damage has not been investigated. Furthermore, the antimycobacterial properties of 
these compounds in vivo remains unknown. Detection of phosphorylated histone H2Ax 
(γ-H2Ax) in mammalian cells by flow cytometry similarly to foci quantification, is a reliable 
high-throughput bio-indicative analysis for chemically induced DNA damage [143-145]. 
Quantification of γ-H2Ax detection by foci formation and flow cytometry in CHO-9 cells 
treated with 14-well-known genotoxic compounds of which H2O2 was amongst them and 
10 non-genotoxic compounds, revealed that the induction of γ-H2Ax expression was 
associated with loss of cell viability in a dose dependent manner. Furthermore, data 
obtained from foci formation and flow cytometry showed high correlation, suggesting that 
flow cytometry analysis of γ-H2Ax detection as high-throughput analysis for genotoxicity 
[143]. Here, observed low detection of γ-H2Ax with both our MGBs and MGB in NIV 
formulation in mammalian cells in murine macrophages compared to cells treated with 
10μM genotoxic agent H2O2 and DMSO (Figure 3A). These data correlate with our 
previous studies on cell viability. Macrophages infected with HN878 remained viable 
following 5 day treatment with MGB 362 and 364 as both free compound and in 
formulation [136]. We used 10µM for treatment as this was shown to be the minimum 
dose to trigger the onset of γ-H2Ax detection by H2O2. These data thus suggest that 
MGB 362 and MGB 364 are not toxic to mammalian cells. However, additional studies to 
verify MGB-induced genotoxicity through foci quantification and other methods are in 
progress. 
 
We next investigated these compounds for their in vivo efficacy during Mtb infection. We 
targeted the site of infection through intranasal administration of MGB compounds and 
MGB-NIV formulation using rifampicin as a control. Intranasal administration of vaccines 
or drugs against tuberculosis has been reported to be more effective compared to other 
routes of administration when doses are exceeding normal clinical doses of most drugs 
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0.1mg/kg [152]. Rosada et al. 2008 [153] reported that a single intranasal dose of the 
formulation of DNA-hsp65 complexed with cationic liposomes as delivery system 
significantly reduced bacterial burden and as effective as four intramuscular 
administrations. Pandey et al. 2003 [154] showed that single nebulization of rifampicin, 
pyrazinamide and isoniazid encapsulated in poly (DK-lactide-co-glycolide) nanoparticles 
was equivalent to 46 daily doses of oral treatment to clear Mtb bacilli in infected guinea 
pigs. Here, we demonstrated that single weekly administrations of MGB 364 and MGB-
NIV 364 at a low concentration (0.5 mg/kg) were effective to reduce bacterial load one 
log-fold in lungs with no effect on the spleen of mice infected with a high dose of 
hypervirulent Mtb strain (Figure 3.2A-C). Surprisingly, empty-NIV administration also 
reduced bacterial load and this was attributed to the previously reported 
immunomodulatory properties of NIV [156]. Our results showed that the presence of 
NIVs in the formulation improved histopathology and increased the levels of effector 
cytokines IL-1α, IL-17 and IFN-γ, which are all involved in the pathogenesis and 
clearance of Mtb infection (Figure 3.3; 3.7A). However, MGB 364 treatment did not show 
any effect on the pathology or immune responses, nor the L-arginine metabolic pathway 
as shown by iNOS or Arginase 1 expression in lung tissues (Figure 3.5). Although the 
use of non-ionic surfactant vesicles (NIVs) showed to be reliable delivery system to 
improve the efficacy of MGBs and deliver to the site of infection, more studies on drug 
permeability and pharmacokinetics to measure the bioavailability of the compounds and 
formulation to the site of infection are warranted. On the contrary, 10 mg/kg of MGB 362 
and rifampicin had no effect on bacterial load (Figure 3.2D-F). Rifampicin is usually 
administered orally or intravenously and is fast absorbed after oral administrated [155]. It 
is possible that the intranasal route of administration did not allow absorption of the drug 
and thus deemed it ineffective against Mtb. Oral administration of MGB 362 similarly not 
have effect on bacterial burden. Rifampicin showed one log-fold reduction compared to 
saline group, however, was not statistically significant (Figure 3.2G-I). Furthermore, 
rifampicin improved pathology due to unclear mechanisms. Although treatment with 
rifampicin increased the recruitment of monocyte derived dendritic cells which are 
responsible for the recruitment of other cell types like CD 4 T-cells that are important for 
the Mtb clearance, treatment with rifampicin did not show any effects on T cell 
recruitment nor immune cytokine production. Surprisingly, treatment with MGB 362 
increased CD4 T cell recruitment (Figure 3.8). However, there was no correlation with 
the cytokines produced nor bacterial burdens in lung tissues. We observed a reduction in 
pro- inflammatory cytokines, IL-1β and IL-12p40 predominantly released by macrophages 
and dendritic cells in the control of acute Mtb infection together with the reduced levels of 
regulatory cytokine IL-10 (Figure 3.7C). IL-12p40 is an essential cytokine in the 
recruitment and activation of CD4 T cells which would mainly release IFN-γ, a key 
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cytokine responsible for Mtb clearance [156, 157]. However, MGB 362 treatment did not 
affect the production of IFN-γ nor Mtb clearance as IFN-γ levels and bacterial loads 
remained similar across groups. 
In conclusion, this study showed that our MGB 364 is non-genotoxic to host cells. 
Furthermore, MGB 364 is an active compound against Mtb directly at the site of infection 
in vivo. The use of NIV improved the efficacy of MGB 364 through mechanisms that 
induce host protective immune functions. Thus, MGB 364 holds promise as an anti-TB 
compound. This warrants further mechanistic screening to determine the mode of action 
of these compounds 
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Figure 3.1: No genotoxicity was observed in MGB 364/MGB-NIV 364 treated macrophages. 
CD11b+F4/80+MHCII+ bone-marrow derived macrophages treated with 10µM MGB-364, MGB-
NIV 364, H2O2, RIF and DMSO. Intracellular detection of γ-H2Ax expression was measured 4, 24 
hrs post-treatment by flow cytometry using isotype control as a measure of detection. Data show 
mean ± SEM of triplicates. Two-tailed Student’s t-test, *P < 0.05, **P < 0.01 compared to isotype 
control. 
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Figure 3.2: MGB-364 and MGB-364 NIV formulation reduced mycobacterial burden in 
HN878-Mtb infected mice but MGB-362 in vivo treatment did not affect mycobacterial load. 
Mice (n= 3-6 per group) were infected with 100 or 1000 CFU of HN878-Mtb strain via intranasal 
challenge followed by weekly single  intranasal treatment with 0.5 mg/kg of MGB-364; 0.5 
mg/kg:30 mM MGB-NIV 364 or 10 mg/kg MGB-362 or 10 mg/kg rifampicin as positive control or  
left untreated; empty NIV or administered saline as negative controls starting one week post-
infection for a duration of 3 weeks. Mice were sacrificed at 4 weeks post-infection (3 weeks post-
treatment) and lungs isolated and homogenized for CFU assays. A) Bacterial load measured in 
lungs B) and spleen  of infected mice intranasally treated with MGB-364, MGB- 364 NIV or empty 
NIV. C) Lung weight index of infected mice intranasally treated with MGB-364, MGB-364 NIV or 
empty NIV. D) Lung and E) spleen bacterial loads of infected mice intranasally treated with MGB-
362 or rifampicin. F) Lung weight index of infected mice intranasally treated with MGB-362 or RIF 
4 weeks post-infection. G) Bacterial load measured  in lungs and H) spleen of infected mice orally 
treated with MGB-362 or RIF. I) Lung weights of infected mice orally treated with MGB-362 or 
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RIF. Data show mean ± SEM of triplicates. One-way ANOVA, *P < 0.05, **P < 0.01; compared to 
no-treatment control. 
 
 
Figure 3.3: NIV encapsulation of MGB-364 improved pulmonary histopathology of HN878-
Mtb mice. Mice (n= 3-6 per group) were infected with 1000 CFU of HN878-Mtb strain via 
intranasal challenge followed by weekly intranasal treatment with 0.5 mg/kg of MGB-364; MGB-
NIV 364 or empty NIV as control or left untreated for 3 weeks. Mice were sacrificed 4 weeks post-
infection (3 weeks post-treatment) and lungs isolated and collected in 4% formalin for 
histopathology analysis. A) Representative images of H&E stained sections. B) Quantification 
of alveolar air spaces 4 weeks post- infection. Data show mean ± SEM of triplicates. One-way 
ANOVA, *p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001 compared to control. 
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Figure 3.4: MGB-362 had no effect on pulmonary pathology. Mice (n= 3-6 per group) were 
infected with 100 CFU of HN878-Mtb strain via intranasal challenge followed by weekly 
intranasal treatment with 10 mg/kg of MGB-362 or rifampicin as positive control or left 
untreated or administered saline as negative control for 3 weeks. Mice were sacrificed 4 
weeks post-infection (3 weeks post-treatment) and lungs isolated and collected in 4% formalin 
for histopathology analysis. A) Representative images of H&E stained sections. B) 
Quantification of alveolar airspaces 4 weeks post- infection. Data show mean ± SEM of 
triplicates. One-way ANOVA; *p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001 compared to 
control. 
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Figure 3.5: MGB-364 and NIV encapsulation had no effect on lung iNOS and Arg1 
expression. Mice (n= 3-6 per group) were infected with 1000 CFU of HN878-Mtb strain via 
intranasal challenge followed by weekly intranasal treatment with 0.5 mg/kg of MGB-364; MGB-
NIV 364 or empty NIV as control or left untreated for 3 weeks. Mice were sacrificed 4 weeks post-
infection (3 weeks post- treatment) and lungs isolated and collected in 4% formalin for 
histopathology analysis. Representative images of iNOS (A) and Arg1 (C) stained sections are 
shown. Percentage of lung iNOS (B) and Arg1 (D) positive areas are quantified in the sections of 
mice 4 weeks post-infection. Data show mean ± SEM of triplicates. One-way ANOVA, *p < 0.05, 
**p < 0.01; ***p < 0.001; ****p < 0.0001 compared to control. 
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Figure 3.6: MGB 362 had no effect on lung iNOS and Arg1 expression. Mice (n= 3-6 per 
group) were infected with 100 CFU of HN878-Mtb strain via intranasal challenge followed by 
weekly intranasal treatment with 10 mg/kg of MGB 362 or rifampicin as positive control or left 
untreated or administered saline as negative control for 3 weeks. Mice were sacrificed 4 weeks 
post- infection (3 weeks post-treatment) and lungs isolated and collected in 4% formalin for 
histopathology analysis. Representative images of iNOS (A) and Arg1 (C) stained sections are 
shown. Percentage of lung iNOS (B) and Arg1 (D) positive areas are quantified in the sections of 
mice 4 weeks post-infection. Data show mean ± SEM of triplicates. One-way ANOVA, *p < 0.05, 
**p < 0.01; ***p < 0.001; ****p < 0.0001 compared to control. 
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Figure 3.7: Increased pro-inflammatory effector cytokine in lungs of MGB-NIV 364 and 
reduced pro-inflammatory cytokine responses MGB 362 treated mice following HN878-Mtb 
infection. Supernatants from lung homogenates were collected for cytokine production analysis. 
A-B) Cytokine concentrations of mice treated with MGB-NIV 364. C) Cytokine concentrations of 
mice treated with MGB-362 or rifampicin. Data show mean ± SEM of triplicates. One-way ANOVA, 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to control. 
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Figure 3.8: Increased CD4 T cell recruitment responses in MGB 362 treated mice following 
HN878-Mtb infection. Mice (n= 3-6 per group) were infected with 100 of HN878-Mtb strain via 
intranasal challenge followed by weekly intranasal treatment 7 days post-infection with 10 mg/kg 
MGB 362 or rifampicin as positive control or left untreated or administered saline as negative 
control with for 3 weeks. Mice were sacrificed 4 weeks post-infection (3 weeks post-treatment) 
and cellular infiltration analysed from lung cell suspensions by flow cytometry A) Percentage of 
lymphocyte cell populations: (CD3+) T-cells; (CD3+CD4+) T-cells; (CD3+CD8+) T-cells; 
(CD3+TCRgd+) T-cells; (CD3-CD19+) B-cells; (CD4-NK1.1+) natural killer (NK) cell. B) Percentage 
of myeloid cell populations: (CD11b+Ly6G+) neutrophils; (CD11b+F4/80+Ly6G-) interstitial 
macrophages; (CD11c+SiglecF+) alveolar macrophages; (CD11b+SiglecF+) eosinophils; 
(CD11b+MHCII+CD11c+CD103-) mDCs; (CD11b+Ly6C+) monocytes from lung single cells 
suspensions of mice treated with MGB-362 or rifampicin. Data show mean ± SEM of triplicates. 
Two-tailed Student’s t-test, *p < 0.05, **p < 0.01 compared to control. 
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The role of IL-4i1 on immune homeostasis during steady-steady and 
Mycobacterium tuberculosis infection
77 
 
 
Chapter 4  
Manuscript in preparation 
IL-4i1 regulates in vivo local T-cell activation and proliferation at 
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Summary  
 
In this chapter we addressed the role of L-phenylalanine, IL-4i1 on immune homeostasis 
steady-state in vivo using IL-4i1 gene-deficient mice models. IL-4i1 has been reported to 
promote the generation of Foxp3+ regulatory T-cells and inhibit the proliferation of 
effector and memory T-cells in vitro, inhibit B-cell activation and polarize macrophages 
towards an M2 phenotype, making the enzyme a potential regulator of host immunity in 
vivo. An in-depth characterization of IL-4i1 deficient mice and littermate controls was 
performed. We first assessed whether gene deletion would not cause any systemic 
impairment. We showed that  IL-4i1 plays a role on activation and proliferation of CD 4 
T-cells in spleen and lungs at steady-state in vivo and that IL-4i1 is important for immune 
homeostasis, null mutation or deletion could lead to autoimmunity. The PhD candidate 
performed all validation PCR, qPCR and flow cytometry experiments to confirm IL-4i1 
deletion by herself presented in Figure 4.2. She performed all body and organ weight 
experiments in Figure 4.3 with Dr Justin Komguep Nono ,Dr Mumin Ozturk and Mr Julius 
Chia. She performed all flow cytometry experiments in Figure 4.4, 4.5, 4.7 and 4.8 with 
Dr Justin Komguep Nono, Dr Mumin Ozturk and Mr Julius Chia. She performed 
immunohistochemistry quantification experiments in Figure 4.6 by herself, validation of 
the absence morphological differences was performed by pathologist Dr Dhiren 
Govender. The candidate performed all flow cytometry in 4.9-4.11 by herself, metabolic 
experiments in 4.12 with Dr Maribanyana Lebeko, and ELISA experiments in Figure 4.13 
by herself. 
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4.1 Abstract  
 
Objectives: Amino-acid catabolizing enzymes have gained attention over the past few 
years on their role of maintaining immune homeostasis mostly through their role on T-
cells under inflammatory or autoimmune conditions. IL-4i1, an IL-4 activated gene is a 
secreted L-amino acid oxidase expressed and secreted by professional antigen 
presenting cells. The enzyme acts by degrading essential amino acids phenylalanine 
(Phe) to produce toxic derivatives like phenylpyruvate, hydrogen peroxide and ammonia. 
Recent studies have reported the ability of the enzyme to promote the generation of 
Foxp3+ regulatory T-cells and inhibit the proliferation of effector and memory T-cells in 
vitro making the enzyme a potential regulator of host immunity in vivo. Here we 
investigated the immunomodulatory role of IL-4i1 in regulating immune homeostasis at 
steady-state in the absence of inflammation through loss of function mouse. 
 
Methods: To address the relevance of IL-4i1 on immune homeostasis in vivo, we 
generated a BALB/c IL-4i1 deficient mouse model that was backcrossed to BALB/c wild- 
type mice for nine generations to obtain a congenic background. To eliminate possible 
flanking gene confounders as a result of mice genetic backgrounds, we used ‘the 
reverse F2 strategy”. An in-depth characterization of IL-4i1-/- mice at different 
generations compared to their littermate controls was performed to assess any 
physiological, tissue, cellular or immunological defects using qPCR, 
Immunohistochemistry, Flow cytometry and ELISA. Additionally we investigated the role 
of IL-4i1 on  the metabolic activation of T-cells by assessing their energy phenotypes of 
in IL-4i1-/- compared to WT littermate controls. 
Results: We observed a systemic dysregulation at the early generations of breeding 
marked by an imbalance in the distribution of myeloid and adaptative immune cell 
distribution in thymus, spleen and lungs as well as an increase in serum IL-12p70, TNF-
α and IFN-γ of IL-4i1-/- compared to WT. However this dysregulation stabilized at 9 
generations. At 9 generations the true immunological functional role of IL-4i1 at steady 
state could be elucidated. We observed an increase in the activation and proliferation of 
T-cells which were marked by increased CD4CD44+ effector and CD4CD44Ki67+ 
proliferating T-cells as well as an increase in their metabolic energy status in the spleen, 
while Foxp3+ T-reg cells were reduced in the lungs of IL-4i1-/- compared to WT. 
Immunochemistry analysis of the spleen showed no differences in tissue morphology of 
spleen, whereas  a slight change was observed in the lung with increased alveolar 
airspace in IL-4i1-/- compared to WT. Additionally, IL-4i1 deficiency promoted the 
differentiation of CD4 T-cells to effector subsets Th1, Th2 and Th17 subsets. 
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Conclusions: Collectively and unprecedentedly, our data indicate a critical role of an L-
amino acid oxidase, IL-4i1, in the maintenance of local immune homeostasis at steady 
state, potentially showing an important role in autoimmunity. 
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4.2 Introduction 
Immune homeostasis is governed by mechanisms which maintain a functional and diverse 
pool of lymphocytes that are would be responsive to foreign pathogens while tolerant to 
self-antigens [158, 159]. Amongst other cell types, T-cell homeostasis is the most 
described. The survival of naïve T-cells is mostly governed by contact with self-antigens 
which categorizes the survival of different repertoire of T-cells. Naïve-antigen T-cell rely 
on self-antigen contact via T-cell receptor, MHC II interactions and IL-7 while memory T- 
cells pre-exposed to self-antigen rely mainly on contact with IL-15 independently of MHC- 
II. Naïve regulatory T-cell survival on the other rely mainly on contact with IL-2 [158-160]. 
The homeostatic equilibrium is altered as naive T-cells routinely migrate from the thymus 
into secondary lymphoid tissues and peripheral tissues, differentiate into effector T-cells 
upon antigen stimulation and form memory T-cells [161]. Some of these peripheral T-cells 
recirculate in the thymus and affect thymocyte development accounting for 1-5 % of 
single-positive thymocytes. For example, recirculation by IL-4/STAT6 signaling activated 
Th2 cells results in decreased numbers of double-positive thymocytes, resulting in overall 
decrease of thymocytes [162]. The success of adaptive immune responses against 
pathogens lies primarily on changes in cellular metabolic pathways of these cells which 
dictate the activation status, survival and function of all immune cells. Amino-acid 
catabolizing enzymes have gained attention over the past few years on their role of 
maintaining immune homeostasis mostly through their role on T-cells under inflammatory 
or autoimmune conditions. One such enzyme, is the L-tryptophan first-rate catabolising 
enzyme, Indoleamine 2,3-dioxygenesae-1 (IDO-1) presented by antigen presenting cells. 
The depletion of L-tryptophan via the kynurenine pathway, leads to the formation of 
tryptophan metabolites, including quinolinic and picolinic acid which in-turn inhibits T-cell 
proliferation [163]. 
Similarly, the L-phenylalanine oxidase, IL-4i1 has gained insight over the years for its 
peculiar immunomodulatory role in tumours and inflammatory disease status and has 
recently been implicated in the development of immune cells. IL-4i1 gained its name due 
to the early discovery of expression in B-cells. The expression of isoform 1 of the gene 
previously identified as Fig-1 was restricted to lymphoid tissues. It was first identified to 
be expressed in B-cells following in vitro stimulation of splenic B cells by the cytokine IL- 
4 via NFκB and STAT6 signaling [164]. It was later discovered in other antigen presenting 
cells of myeloid lineage as a secreted enzyme and later identified to be expressed in T- 
helper 17 cells [89]. The enzyme catabolizes phenylalanine (Phe) into phenylpyruvate and 
produce toxic derivatives, hydrogen peroxide and ammonia [89]. Its capacity to produce 
H2O2 has been reported inhibit the proliferation and cytokine production of effector T-cells 
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mostly associated with anti-tumour responses in vitro. However, it was recently discovered 
that IL-4i1 downregulates TCR downstream activation signals irrespective of it enzymatic 
activity [165]. IL-4i1 has also been reported to promote the generation of Foxp3+ 
regulatory T-cells from naïve CD4+ T cells [89, 91]. The expression in Th17 was attributed 
to its role in the control of cell cycle-progression by limiting the production of IL-2 and 
through maintaining high levels of Tob1 transcription factor. IL-4i1 has been detected in 
B-cells of germinal centres [165]. Recently, it has been implicated in the development 
and activation of B-cells as a negative regulator of the BCR Syk-Akt-S6 kinase activation 
pathway [93]. 
In vivo studies have identified anti-proliferative role of IL-4i1 in CD8 T-cells in a tumour 
model. In a spontaneous in vivo melanoma model, IL-4i1 knockout mice showed delayed 
tumour progression accompanied by an infiltration of Th1 cell and CD 8 T-cells [94]. In a 
multiple sclerosis model, IL-4i1 knockout mice had increased T-cell proliferation in the 
brain and peripheral tissues. However; in the presence of IL-4i1, T-cell expansion was 
reduced and recruitment and survival of oligodendrocytes was increased, thus showing 
the importance of IL-4i1 in remyelination [95]. Here we investigated the 
immunomodulatory role of IL-4i1 in regulating immune homeostasis at steady-state in the 
absence of inflammation through loss of function mouse model which could decipher IL- 
4i1 as possible role of autoimmune disease. 
The generation of knockout mouse by homologous recombination was carried in 
embryonic stem cells of 129Sv mouse inbred strains. However due to poor breeding 
quality of these mice, the resulting knockout mouse is usually crossed to wild-type 
C57BL/6 mice [54, 166]. We generated a BALB/c IL-4i1-/- by backcrossing to BALB/c wild- 
type mice for nine generations. The importance of backcrossing to at least 10 generations 
to obtain a congenic background is attributed to the confounding influence of genetic 
background. In many studies it has been difficult to elucidate whether the underlying effect 
is of the null mutation or traces of the genetic background, termed the “flanking gene” or 
“passover gene” [166-168]. The resulting F2 generation would contain a segregation of 
the null mutation and that of the parental allele [167]. The resulting segregation would not 
cause serious problems, however could influence behavioural and immunological roles of 
genes as is the case for IL-10 knockout mice [166]. We characterized our mouse models 
at different generations of breeding to eliminate the effect of “flanking genes” from genetic 
background. We observed a systemic dysregulation at the early generations of breeding 
that stabilized with more backcrossing. At 9 generations the true immunological functional 
role of IL-4i1 at steady state could be elucidated. We report on the role of IL-4i1 on tissue 
84 
 
localized T-cell activation and proliferative status thus a role in the maintenance of local 
immune homeostasis at steady state, potentially important role in autoimmunity. 
 
4.3 Materials and Methods 
 
4.3.1 Mice 
The mouse strain used for this research project, B6;129S5-Il4i1tm1Lex/Mmucd, 
identification number 011726-UCD, was obtained from the Mutant Mouse Regional 
Resource Center, a NIH funded strain repository, and was donated to the MMRRC by 
Lexicon Genetics, Inc. It was then resuscitated. Chimeric mice were bred to C57BL/6J 
albino mice to generate F1 heterozygous mice which were then inter-crossed to produce 
wild-type, heterozygous and homozygous mutant progeny. Mice from this progeny were 
backcrossed 9 generations to wild-type BALB/c mice. All experimental mice were 
matched for sex and age and used between 8-12 weeks of age. Mice were kept under 
pathogen-free conditions in individually ventilated cages the University of Cape Town’s 
animal facility unit Biosafety level 2 (BSL-2). Animal room temperature was maintained 
at 22-25 ˚C and 12 hours light/dark cycle. Food pellets and water were made available 
ad libitum. 
 
4.3.2 Ethical Statement 
All experimental procedures were carried in accordance with the South African National 
Standard (SANS 10386:2008). The protocol (015/037) was approved by the Ethics 
Committee, University of Cape Town. 
 
4.3.3 Genotyping and Confirmation of IL-4i1 deletion 
Polymerase chain reaction was used for genotyping of mice. DNA from tail biopsies and 
splenocytes of naive IL-4i1-/- mice and control littermates were isolated for confirmation of 
IL-4i1 deletion with the following primer sequences: Neo3a forward 5’- 
GCAGCGATCGCCTTCTATC-3’ and reverse 5’-GTGCTCACTTCCTCTTTGCGACT-3’ 
and wild-type primers: forward 5’-TTGAGACCTTTCTTTCCGAGCAG-3’ and reverse 5’- 
AGGCTAAACCTTG-3. Briefly 500μl lysis buffer was added to each sample followed by 
overnight rotating incubation at 56°C. The samples were then centrifuged at 100rpm for 
10mins. Supernatants were replaced with 500μl isopropanol, mixed gently and 
centrifuged at 1000rpm for 6mins. 1ml of supernatants were removed followed by 
incubation with 70% ethanol at -20°C for 10mins. Ethanol was then discarded, samples 
centrifuged at 10000rpm for 2 mins, excess ethanol removed and tubes were left open 
for ethanol to evaporate. Sample tubes were then heated on heating block for 20 mins 
for DNA to resuspend. PCR was performed in 50μl reaction mixtures containing 5ul 10x 
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buffer, 3μl MgCl2 final concentration 25μM  (stock 25mM), 3μl dNTPs (250μM), 2ul DNA, 
0.07μl supertherm taq polymerase (1.5 U), 3μl mutant Neo3a forward primer (6.25 μM), 
3μl mutant reverse primer (6.25μM); 3μl wild-type forward primer (6.25μM); 3μl reverse 
primer (6.25μM) and 22.93 of PCR water. The PCR cycle started with initial denaturation 
step at 94°C for 2 mins followed by 39 cycles of denaturation at 94°C  for 20 seconds, 
annealing at 58°C for 30 seconds, extension at 72°C for 1.30 mins and final extension at 
72°C for 5 mins. The PCR product was separated by electrophoresis on ethidium 
bromide-stained agarose gel, followed by visualization under UV light. The amplicon 
fragment for wild-type was 325 bp and 187bp for IL-4i1-/-.Confirmation of IL-4i1 deletion 
from spleen isolated from IL-4i1-/- and tissues from wild-type littermate control was 
performed by quantitative PCR amplicon 200bp normalised to HPRT 1. 
 
4.3.4 Quantitative tissue expression of IL-4i1 
Total RNA was extracted by RNAeasy kit from Qiagen and reverse transcribed by 
Transcriptor First Strand cDNA Synthesis Kit (Roche) according to manufacturer’s 
instructions. Real-time PCR was performed with LightCycler® 480 SYBR Green I Master 
mix in LightCycler® 480 II (Roche). Quantitative tissue expression analysis of IL-4i1 was 
normalized against the housekeeping gene Hprt1 with primers forward 5’- 
GGCCATGAGGCTGGATCTC-3' and reverse 5'-GGCCATGAGGCTGGATCTC-3’. IL-4i1 
5’-ATTCCCCAGAGGACATCTACCA-3and reverse5’ CTGTACCGGAGTCTATCGCTCA-
3’. 
 
4.3.5 Flow Cytometry 
Single cell suspensions from thymus, spleen and lung tissues were stained for surface 
markers with the following antibodies: F4/80 (PE-Cy7) from Affymetrix eBiosciences; CD4 
(PerCP-Cy 5.5 or PE or FITC); CD11c (V450 or A700 or APC); CD11b (PercP-Cy 5.5); 
MHCII (A700); CD103 (PE); SiglecF (APC-Cy7 or APC); CD44 (FITC); CD62L (V450); 
CD19 (PerCP-Cy5.5); CD8 (V500); LY6G (APC-Cy7); Foxp3 (APC); CD 80 (V450); 
CD206 (FITC) and Ki67 (PE) from BD Biosciences in FACS buffer (1X PBS with 1% BSA 
and 0.1% NaN3). Rabbit polyclonal IL-4i1 antibody and goat anti-rabbit secondary IgG 
(PE) purchased from Abcam. For surface staining, cells (1x106) were labelled and washed 
with PBS containing 0.1% BSA (Roche, Switzerland) and 0.1% NaN3. For intracellular 
staining, we used the BD Pharmingen Transcription Buffer Set (BD Biosciences) as per 
manufacturer’s instructions to detect Foxp3 and Ki67 expression. Acquisition was 
conducted using BD LSR Fortessa, and data analysis was performed with FlowJo 
software (Treestar, Ashland, OR, US). 
 
 
86 
 
4.3.6 Cell sorting and ex vivo T-cell differentiation 
CD4+ T-cells were sorted from spleen single suspension of naïve IL-4i1-/- and wild-type 
littermate controls using Easy Sep CD4 T-cell negative selection isolation kits (Stemcell) 
according to manufacturer’s instructions. In vitro differentiation of CD4+ cells into 
Th1/Th2/Th1 or Foxp3+ T-reg cells were induced as previously described by [169]. Cells 
were then cultured in triplicates per group in flat-bottom 96 well plates coated with 20ug/ml 
of plate-bound anti-CD3. After 96 hours incubation, cells were re-stimulated with 250ng/ml 
ionomycin and 50ng/ml phorboyl 12-myristate 13-acetate (PMA) and Brefeldin A (BFA) to 
a final concentration of 80nM to culture medium. Cells were then permeabilized for 
intracellular and intranuclear immune-staining for detection of transcription factors and 
hallmark cytokines T-bet, IFN-γ; Gata-3, IL-4; Rorγt, IL-17 and Foxp3 for Th-1, Th-2, Th- 
17 and T-regulatory cells, respectively. 
 
4.3.7 Metabolic activity 
To determine the metabolic status of splenic T-cells from IL-4i1 deficient mice, CD3+CD4+ 
T-cells of single suspension from spleen of naïve IL-4i1-/- and wild-type littermate controls 
were sorted using FACS Aria and cultured in RPMI1640 media containing 10% FCS and 
0.5% Pen-Strep overnight. Cells were then stimulated with 100U/ml IL-4 or left 
unstimulated for 24hrs. To measure the energy status of T-cells, we used Agilent 
Seahorse XF 96 analyzer to measure oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) as an indicator of glycolysis stress as described in [170]. 
 
4.3.8 Histology 
Formalin fixed (4%) spleen and lungs from wild-type littermate controls and IL-4i1-/- mice 
were stained with hematoxylin and eosin as described [80, 151]. Gelatine-based 
mounting medium was used to mount the sections. Image acquisition and quantification 
of alveolar airspaces were performed using NIS advanced software on a Nikon (Tokyo, 
Japan) 90i microscope. Percentage of free alveolar airspaces was defines as the area of 
ventilated spaces in whole lung sections in relation to the total lung tissue area using the 
area measurement tool by NIS advanced software on a Nikon 90i microscope and % 
alveolar spaces calculated using Excel as described [21].  
 
4.3.9 The enzyme-linked immunosorbent assay 
Blood samples from IL-4i1-/- and wild-type littermate controls were collected by cardiac 
puncture upon sacrifice. Serum samples were used to determine systemic cytokine 
production using enzyme-linked immunosorbent assay. IL-12p70, TNF-α, IL-10, IFN-γ and 
IL-4 (All from BD Biosciences) production was measured from the supernatants and data 
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analysed using SoftMax Pro 6. 
 
4.3.10 Statistical Analysis 
 
All data were analysed using Graph-Pad Prism 6.0, student t-test (two-tailed with equal 
variance) was used. A *p value of less 0.05 was considered significant, with **p < 0.01, 
***p < 0.001 and ****p < 0.0001
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4.4 Results 
 
4.4.1 Generation and genotyping of IL-4i1-/- mice 
To understand the functional role of IL-4i1 on immune homeostasis at steady state in 
vivo, IL-4i1 knockout mice were resuscitated from B6;129S5-Il4i1tm1Lex/Mmucd, 
identification number 011726-UCD, obtained from the Mutant Mouse Regional Resource 
Center, a NIH funded strain repository, and donated by MMRRC by Lexicon Genetics, 
Inc. Chimeric mice were  then mated with C57BL/6 mice to generate heterozygous F1 
generation consisting of 50:50% IL-4-/+. F1 generation was inter-crossed to yield 25% IL-
4i1+/+; 50% IL-4i1-/+ and 25% IL-4i1-/-. The resulting homozygous IL-4i1-/- mice were 
further backcrossed to BALB/c mouse line for 9 generations to obtain an inbred mouse 
of IL-4-/- and littermate controls of BALB/c genetic background (Figure. 4.1B). Genomic 
PCR from tail biopsies from IL-4i1-/- mice confirmed the deleted allele with amplicon of 
187bp compared to wild-type allele of 325bp (Figure. 4.2A). Conventional PCR and 
agarose gel electrophoresis showed IL-4i1 expression in thymus, liver, lung, spleen and 
heart with no expression in IL-4i1 deletion in spleen (Figure. 4.2B). Expression of IL-4i1 
mRNA by qPCR in brain, thymus, heart, lung, liver, mesenteric lymph nodes, spleen, 
colon and gut showed that colon has the highest IL4i1 mRNA levels with no expression 
of IL-4i1 in knockout mice (Figure 4.2C). We confirmed the deletion of IL-4i1 protein by 
flow cytometry in CD3+CD4+ T-cells, CD3+CD8+ T-cells, CD19+ B-cells, CD11b+F4/80+ 
macrophages, CD11b+CD11c+ dendritic cells of the spleen. The fluorescence levels in IL-
4i1-/- were comparable to isotype control as indicated in the histogram plot and the 
geometric means (Figure. 4.2D-E). Although other cell types express IL-4i1, 
macrophages and dendritic cells showed the highest expression of IL-4i1 compared to 
lymphocytes B-cells and T-cells in WT littermate control splenocytes (Figure. 4.2F), 
suggesting that the myeloid APC’s are the key sources of IL-4i1 secretion in murine 
models at steady state in vivo in conformity with previous findings on human IL-4i1 [89]. 
 
4.4.2 Phenotypic characterization of IL-4i1-/- mice 
To assess whether IL-4i1 deletion probes any phenotypic impairment on the IL-4i1-/- 
mouse model, we assessed for impairments in body weights, organ development, and 
cell numbers in WT littermate control and IL-4i1-/- at the different stages of mouse 
generation (F2, F7 and F9). There were no aberrant alterations in the physiology or 
development of WT littermate control and IL-4i1-/- mice across all three generations 
investigated. Body weights and organ weights (liver, lung, heart and spleen) were 
comparable between WT littermate control and IL-4i1-/- except for the liver at F2 
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generation (Figure. 4.3A-E). These results suggest an impairment in liver tissue 
development in the absence of IL-4i1 at F2 IL-4i1-/- progeny. However, this impairment 
was rescued at later generations. A significant reduction in lung weights of IL-41-/- mice 
when compared to WT controls were observed at F9 generation (Figure.4.3D). These 
data suggest no major physiological impairments in the absence of IL-4i1 at steady state 
in IL-4i1-/- mice of congenic BALB/c genetic background. 
 
 
4.4.3 Functional characterization of IL-4i1 deletion on T-lymphocyte development 
To determine whether IL-4i1 deletion would cause impairment on T-cell development at 
steady state in vivo, we compared the frequency of (CD4-CD8- Double Negative [DN]; 
CD4+CD8+ Double-Positive [DP]; CD4+CD8- Single-Positive 4 [SP4] and CD4-CD8+ 
Single- Positive 8 [SP8] thymocyte subsets between WT littermate control and IL-4i1-/- 
mice at F7 and F9 generations. A dysregulation in thymocyte development was 
observed at F7 generation. A significant increase in DN cells (p<0.001) (Figure. 3.4A), 
but a significant reduction in DP cells (p<0.001) (Fig. 4B); followed by increased 
frequencies of SP4 and SP8 (p< 0.001) (Figure. 4.4C-D) in IL-4i1-/- compared to WT 
littermate control mice. However, this effect was not seem at F9 generation; DN, DP and 
SP4 percentages were comparable between WT littermate control and IL-4i1-/- mice 
(Figure. 4.4A-D). It is thus important to note that the major differences observed at F7 
between WT and IL-4i1-/- were not observed at F9 generation thus suggesting that IL-4i1 
deletion in BALB/c mice does not have an effect on T-cell ontogeny. 
 
 
4.4.4 IL-4i1 deletion does not alter immune cell distribution but probes T-helper 
cell activation in secondary lymphoid tissues 
To determine whether IL-4i1 deletion would alter immune homeostasis in lymphoid 
tissues at steady state in vivo, we evaluated the overall distribution of immune cells in 
secondary lymphoid tissue, spleen of WT littermate control and IL-4i1-/-. IL-4i1 deletion 
did not result in striking changes in spleen morphology (Figure. 4.5A). We observed a 
slightly imbalanced distribution of the lymphocyte compartment in spleens of IL-4i1-/- at 
earlier generations. CD19+ B-lymphocyte distribution was significantly increased (p<0.05) 
in IL-4i1-/- compared to WT at F7 generations (Figure. 4.5B). There were no differences 
in distribution at F9 generation in these subsets. CD3+ total T-cells and CD3+CD4+ T-
helper subset distributions were not affected by IL-4i1 deletion in spleens of IL-4i1-/- 
compared to WT littermate controls across all generations (Figure. 5C-D). However, 
percentages of CD3+CD8+ cytotoxic T-lymphocyte subset was significantly reduced F2 
generation but increased in IL-4i1-/- compared to WT at F7 generation (p<0.01). However, 
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these differences were not seen at F9 generation (Figure. 5D). IL-4i1 has previously 
been reported to suppress effector T-cell activation, proliferation and facilitate the 
development of regulatory T-cells through mechanisms that involve the inhibition TCR 
downstream signaling events that induce activation and proliferation in vitro [89, 91, 
165]. Next, we sought to evaluate the role of IL-4i1 deletion on the activation status of T-
helper and cytotoxic T-cell subsets and immune tolerance at steady state in vivo. CD62L 
and CD44 markers were used to differentiate effector and naïve T cell subsets. 
Differential expressions of CD62L and CD44 in both T-helper and cytotoxic T-cell 
compartment at early generation (F2 and F7) were observed but were comparable 
between WT littermate control and IL-4i1-/- at F9 generation (Figure. 4.5F-H; J-L). 
However, consistent with the earlier generations, slight increase in effector CD4+ T-helper 
cells was observed, suggesting that absence of IL-4i1 may probe activation of CD4+ T-
helper cells. No differences in Foxp3+ regulatory T-cells were observed between WT 
littermate controls and IL-4i1-/- mice and within the myeloid cell compartment across all 
generations (Figure. 4.5 I, M-N). MHCII expression was decreased in IL-4i1-/- when 
compared to WT littermate controls at earlier generation (F7) in myeloid cells as shown 
by the geometric mean fluorescence of MHCII (Figure. 4.5O), thus suggesting that 
MHCII expression was not affected by IL-4i1 deletion at F9 generation. 
 
4.4.5 IL-4i1 deletion reduces frequency of Foxp3+ T-regulatory cells in lungs in 
vivo  
To evaluate the effects of IL-4i1 deletion on lung immune homeostasis at steady state in 
vivo, we evaluated the overall morphology in lungs of WT littermate control and IL-4i1-/-. 
IL-4i1-/- deletion improved alveolar spaces compared to WT littermate controls and IL-
4i1-/- lung tissues as shown by H&E sections and percentage alveolar airspaces (Figure. 
4.6A-B). IL-4i1 deficiency resulted in significantly increased alveolar airspaces, thus 
suggesting that IL-4i1 deficiency slightly changes lung morphology at naïve state 
(Figure. 5.6B). However, similarly to secondary lymphoid tissues, a dysregulated 
distribution of lymphocyte compartment in lungs of IL-4i1-/- at earlier generations was 
observed. CD19+ B-lymphocyte distribution was significantly reduced in IL-4i-/- compared 
to WT littermate controls at F7 generations (Figure. 4.7A). Distribution of CD3+CD8+ 
lymphocyte subset was significantly reduced (p<0.01) across all generations. A 
reduction CD3+ total T-cells was observed at earlier and later generations, whereas 
CD3+CD4+ T-helper subset distributions stabilized at F9 generation in lungs of IL- 4i1-/-  
compare d to WT (Figure. 4.7B-D). Next, we sought to evaluate the role of IL-4i1 deletion 
on the activation status of T-helper and cytotoxic T-cell subsets. Again, differential 
expression of CD62L and CD44 expression in both T-helper and cytotoxic T-cell 
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compartment at early generation (F2 and F7) were observed but were comparable 
between WT littermate control and IL-4i1-/- at F9 generation (Figure. 4.7E-G; I-K). 
Interestingly a reduction in Foxp3+ regulatory T-cell population measured at F9 generation 
was observed (Figure. 4.7H). No differences were observed in the myeloid cell 
compartment across all generations (Figure. 4A-C). Similarly, MHCII expression was 
decreased in myeloid cells at F9 generation; however similar levels of MHCII expression 
in lungs of IL-4i1-/- mice and WT mice were detected (Figure 4.8D). Notably, the 
activation of T- cells because of IL-4i1 depletion is independent of MHC II expression to 
T-cell interaction at steady state in vivo. Overall, our findings were indicative of systemic 
stabilization in IL-4i1-/- mice of congenic genetic background. 
 
4.4.6 IL-4i1 deletion promotes proliferation of effector T-helper cells and reduces 
proliferation of Foxp3+ regulatory T-cells 
 
Next we sought to evaluate whether the observed activation status of CD4+ T-helper 
cells as marked by the increased expression of CD44+ is related to the proliferative status 
in spleen at F9 generation. We observed a significantly higher (p<0.05) expression of 
proliferative marker Ki67 on CD4+CD44+ effector T-cell (Fig. 4.9A), but a significantly 
reduced (p< 0.01) expression of Ki67 in Foxp3+ regulatory T-cells (Figure. 4.9B) in IL-4i1-
/- mice compared to littermate controls. Comparable overall expression of Ki67 was 
observed for both CD4+ T- helper and CD8+ cytotoxic T-cells between WT littermate 
controls and IL-4i1-/- mice (Figure. 4.9C- D). Contrary to the observed distribution of 
Foxp3+ regulatory T-cells in the lungs, these cells expressed higher levels of Ki67 in IL-
4i1-/- compared to their WT counterparts (Figure. 4.10A). No significant differences were 
observed in Ki67 expression of effector CD44+ effector T-cells and the overall CD4+ T-
helper and CD 8+ cytotoxic T-cells of IL-4i1-/- compared to WT littermate controls (Figure. 
4.10B-D). 
 
4.4.7 IL-4i1 deletion promotes effector T-helper cells differentiation 
IL-4i1 has previously been reported to play a role in the differentiation of Th cells to 
different subsets. Analysis of T-cell differentiation from conventional splenic naïve CD4+ 
(GFP- CD25+CD62L+) cells from Foxp3-EGFP transgenic mice cultured with IL-4i1 
expressing or HEK control cells and naive CD4+ cells from PBMC cultured with THP1 or 
THP1-IL-4i1, showed that IL-4i1 stimulates the generation of FoxP3+ regulatory (T-regs) 
from mouse and human T cells through the ablation of mTORC1 kinase signaling 
pathways in activated CD4+ T cells while limiting the differentiation of T effector (Th1 and 
Th2) cells [91]. Here we validated the role of IL-4i1 on naïve CD4+ T-cell polarization 
through loss of function using splenocytes from IL-4i1-/- mice and WT littermate controls. 
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Isolated CD4+ T-cells were stimulated with polarizing cytokines for each subset. For Th1 
subset, cells were stimulated with IL-2, IL-12 and anti-IL-4; Th2 with IL-2, IL-4, anti-IL-12 
and anti-IFN-γ; Th17 with IL-2, TGF-β, IL-6, anti-IL-4, anti-IFN-γ and anti-IL-12; while for 
T-reg IL-2 and TGF-β were used. The differentiated CD4+ subsets were characterized by 
the expression of transcription factors, T-bet, Gata-3, RORγt and Foxp3. The deletion of 
IL-4i1 promoted differentiation into T-effector subsets showing significant increase (p< 
0.05) in Th17 RORγt expression and an increasing trend in GATA-3 and T-bet 
expressions compared to WT CD 4+ T-cells (Figure. 11A). Functional validation of these 
subsets was confirmed by significant increase in IL-4 and IFN- γ production for Th-2 and 
Th-1 cells respectively in IL-4i1 deficient mice compared to WT mice (Figure. 4.11B). 
 
4.4.8 IL-4i1 deletion activates metabolic state of ex-vivo T-helper cells 
To confirm the role of IL-4i1 deletion on the activation status of CD4 T-cells, we 
evaluated the metabolic status of CD4 T-helper cells isolated from the spleens of IL-4i1-/- 
and WT littermate controls and stimulated with 100U/ml of rIL-4. We measured oxygen 
consumption rate (OCR) as a measure of oxidative phosphorylation and extracellular 
acidification rate (ECAR) as an indicator of glycolytic flux. Mammalian cells usually 
generate energy through oxidative phosphorylation via the mitochondria or through 
glycolysis (non-mitochondrial). Activation of T-cells drives cells into a glycolytic state 
compared to B lymphocytes which use a balance between oxidative phosphorylation and 
glycolysis [170, 171]. The energy map of OCR and ECAR categorizes both stimulated 
and unstimulated IL-4i1-/- T-cells at high energy and glycolytic status compared to the WT 
littermate controls with OCR and ECAR values of 120-180 pmol/min and 5.5-7mpH/min, 
respectively (Figure. 4.12 A-C). These data are in conformity with the proliferation and 
effector phenotype of CD4 T-helper cells observed in the spleen of IL-4i1-/- mice 
compared to WT littermate controls. 
 
4.4.9 Characterization of IL-4i1 deletion on systemic cytokine production 
Next we sought to evaluate whether IL-4i1 deletion would have an effect on systemic 
cytokine production following T-cell activation. Similarly, a dysregulation in serum 
cytokines produced was observed at F2 and F7 generations. Increased levels of IL- 
12p70 were observed in IL-4i1-/- compared to WT littermate controls at F2 generation in 
the absence of IL4i1, but comparable levels were observed at F7 and F9 generations 
(Figure. 4.13A). Significantly increased levels of TNF-α, IFN-γ and IL-4 were observed at 
F7 generation, but were all similar levels at baseline for F9 generation (Figure. 4.13 B-
E). These data suggest distinction between events occurring in the local tissue 
environment and blood circulation. 
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4.5 Discussion 
In this study we evaluate the role of IL-4i1 in the maintenance of immune homeostasis at 
steady state in vivo. We identified the expression of IL-4i1 in various tissues of the body 
thus illustrating an importance of the enzyme in systemic immune regulation. To address 
this, we resuscitated and IL-4i1 knockout mice of 1B6;129S5-Il4i1tm1Lex/Mmucd, 
background, chimeric mice were then crossed with C57BL/6 mice and backcrossed nine 
generations to obtain IL-4i1-/- and WT littermate controls of BALB/c congenic background 
(Figure 4.1). Deletion was confirmed on genomic, mRNA and protein levels from cell 
types and tissues of the knockout and wild-type littermate control mice (Figure 4.2). In 
our study, the knockout mouse of interest originates from three different backgrounds 
and thus backcrossing to many generations was essential to eliminate possible 
confounders. Wolfer et al. addressed possible strategies to deal with flanking genes 
[167]. One possible method was “the reverse F2 strategy. Here we employed a similar 
method where we characterize the resulting IL-4i1 knockout and wild-type littermate 
controls across different generations (F2, F7 and F9). We observed no impairment in the 
physiological and morphological appearance of the knockout and wild- type littermate 
control mice across different generations (Figure 4.3). However, a systemic immune 
imbalance was apparent at earlier generations as illustrated by the dysregulation in 
cellular compartments of myeloid and lymphocyte lineages in various tissues (Figure 4.4, 
4.5, 4.7, 4.8). Furthermore, we notice elevated levels of systemic cytokine production IL-
12p70, TNF-α and IFN-γ at baseline (Figure 4.13). However, this dysregulation was 
balanced at F9 generation. No major differences were observed in cell type distributions 
between IL-4i1-/- mice and wild- type littermate controls in primary, secondary lymphoid 
organs and peripheral tissues. However, the differences observed at F9 generation that 
were consistent with previous findings at F2 generation, these were attributed to the null 
mutation rather than the mouse genetic background. Consistent with previous findings, 
we first identified that the expression of IL-4i1 was greater in myeloid APCs compared to 
other cells types. In line with previous studies on the immunomodulatory functions of IL-
4i1 on T-cell adaptive immune responses in inflammatory conditions and cancer [86, 94, 
95], we identified the role of IL-4i1 in T-cell activation and proliferation in secondary and 
peripheral tissues at steady state in vivo. Deletion of IL-4i1 resulted in elevated 
frequencies of proliferative CD4 effector T-cells and reduced distribution of proliferative 
Foxp3 T-regulatory cells in the spleen at F9 generation (Figure 4.9). Although the 
distribution of Foxp3 T-reg cells was reduced in the lung, its proliferative status was 
elevated as indicated by Ki67 expression (Figure 4.10), thus indicating a tissue specific 
role of IL-4i1 in regulating immune homeostasis. 
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Previous studies reported on the in vitro effect of IL-4i1 secreted by myeloid APCs on the 
downregulation of TCR ζ-chain via its enzymatic activity and H2O2 production thus 
inhibiting T-cell proliferation. In our study, MHC II expression in APCs was not affected at 
F9 generation thus suggestion that the activation of T-cells at earlier generation was 
inversely proportional to the maturity of antigen presenting cells at steady state in 
secondary lymphoid tissues and that the TCR ζ-chain previously reported to be 
downregulated by IL-4i1 [89] works independently of MHCII. Aubatin et al. [165] reported 
that IL-4i1 was secreted at immune synapse and inhibited TCR downstream signaling 
events independently of its enzymatic activity. Cousin et al. [91] reported on the role of 
IL- 4i1 on the development of Foxp3 T-cells. IL-4i1 promoted the generation and 
proliferation of T-reg cells via the inhibition of mTORC1 signaling. In light with these 
findings, we showed that IL-4i1 deletion in reverse promotes the differentiation of CD 4 
effector subset, enhanced for Th1 and Th17 subset (Figure 4.12). Previous in vivo 
studies have identified an anti-proliferative role of IL-4i1 on CD8 tumour cells. Psachoulia 
et al. 2016 [95] showed that IL-4i1 reduced T-cell expansion and supports 
oligodendrocytes survival and remyelination during multiple sclerosis in vivo. 
Interestingly, in that study they used the original F2 generation of the mouse model we 
used. Due to the possibilities of the “flanking gene” effects, it again raises the question 
whether their result was a question of the IL-4i1 mutation or whether genetic background 
had an influence on the results obtained, this remains unclear. To further illustrate the 
role of IL-4i1 on T-cell activation, we measured the metabolic energy status of T cells 
stimulated with IL-4. Here we show the importance of IL-4i1 on the regulating and 
maintaining of balanced adaptive immune-checkpoint at steady-state in vivo. Naïve T-
cells when activated undergo a proliferative chain reactions inducing a metabolic 
remodeling of these cell types governed by anaerobic glycolysis and oxidative 
phosphorylation [171-173]. Although oxidative phosphorylation plays the major role in 
the energy status due to the production of ATP, glycolysis is able to generate metabolic 
intermediates important for cell growth and proliferation [172-174]. Upon activation T-
cells move from a quiescent resting state to an almost complete glycolytic energy state 
[173, 175]. In the absence of IL-4i1, we observed an energy shift that maps cells in the 
higher energetic zone where mitochondrial activation occurs marked by oxidative 
phosphorylation as well as a higher glycolytic state compared to WT littermate 
counterparts when stimulated with IL-4 in naïve T-cells in vitro. These data thus confirm 
the role of IL-4i1 in the activation and proliferation of T-cells by controlling metabolic 
cues that drive cell activation. We noticed that the systemic cytokine production was not 
affected by IL-4i1 deletion at F9 generation irrespective of tissue T-cell activation and 
proliferation. 
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4.6 Conclusion 
Here, we described the importance of IL-4i1 in regulating immune homeostasis at steady 
state in vivo using loss of function mouse models. We showed the importance of 
characterizing gene modified mice at different generations of breeding to extract the 
function of the null mutation from the mouse genetic background. IL-4i1 deletion 
introduced a systemic dysregulation at early generations, but the effect was stabilized with 
a pure congenic mouse. We could thus decipher the important role of IL-4i1 in maintaining 
localised T-cell activation and proliferation through the control of metabolic cues that drive 
T-cell activation status and function. Although we showed an important role of IL-4i1 in 
modulating and maintaining immune homeostasis at steady state in vivo, more 
mechanistic studies on the role of IL-4i1 on localised tissue T-cell activity at steady are 
warranted. Our results highlight the importance of IL-4i1 in the maintenance of immune 
homeostasis and that the absence of this gene could cause autoimmunity.
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Figure 4.1: Generation of IL-4i1 deficient mice: A) Targeting strategy for IL-4i1 genomic locus, 
targeting construct and targeted allele, targeting coding exons 1-7. B) IL-4i1 knockout mice were 
generated in 129s/SvEvBrd embryonic stem cells through homologous recombination through and 
then mated with C57BL/6 mice. The resulting heterozygous IL-4i1+/- mice were backcrossed 9 
generations to wild-type BALB/c mice. 
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Figure 4.2: Genotyping of IL-4i1 deficient mice: A) Deletion of IL-4i1 was confirmed from 
splenocytes of wild-type and IL-4i1 knockout mice. The amplicon fragment for wild-type is 325 bp 
and 187bp for IL-4i1-/-. B) Agarose gel image of IL-4i1 expression from thymus, heart, lung, liver 
wild-type mice, confirming deletion in IL-4i1-/- samples. C) Quantitative PCR analysis of IL-4i1 
expression was analysed from different tissues (brain, thymus, heart, lung, liver, mesenteric 
lymph nodes, spleen, colon and gut) of wild-type BALB/c mice as well as spleen of IL-4i1-/- mice, 
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Il4i1 levels were normalised to Hprt1. D) Confirmation of IL-4i1 deletion by flow cytometry from 
different cell types (CD3+CD4+ T-cells, CD3+CD8+ T-cells, CD19+ B-cells, CD11b+F4/80+ 
Macrophages, CD11b+CD11c+ Dendritic cells) isolated from spleen of IL-4i1-/- (grey) and wild-
type littermate control mice (black), red line represents isotype control. E) Geometric mean 
fluorescence intensity of IL-4i1 in different cell types of spleens from IL-4i1-/- and wild-type 
littermate control mice. F) Cell-type expression of IL-4i1 by flow cytometry in spleens of wild-type 
littermate controls, (CD11b+CD11c+ Dendritic cells, CD11b+F4/80+ macrophages, CD3+CD4+ T-
cells, CD3+CD8+ T-cells, CD19+ B-cells). G) Geometric mean fluorescence intensity of IL-4i1 in 
different cell types. Data are representatives of two independent experiments with at least n= 4-6 
mice per group. Data are shown as mean ± SEM. Student t-test analysis *p<0.05 was used to 
determine significance. 
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Figure 4.3: Phenotypic characterization of IL-4i1 deficient mice across F2, F7 and F9 
generations following backcrossing: A) Body weights of WT littermate control (filled) and IL-4i1 
knockout mice (empty) in a BALB/c genetic background. B-E) Liver, heart, lung and spleen weights. 
Data are presentative of two independent experiments with at least n= 5-10 mice per group. 
Student t-test analysis *p<0.05 was used to determine significance. 
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Figure 4.4: Functional characterization of IL-4i1 deletion on T-cell ontogeny across F2, F7 
and F9 generations of IL-4i1 deficient mice. A) Flow cytometry analysis of percentage 
CD3+CD4-CD8- double-negative (DN); B) CD3+CD4+CD8+ double-negative (DP); C) 
CD3+CD4+CD8- single-positive 4 (SP4) and D) CD3+CD-CD8+ single-positive 8 (SP8) thymic T- 
cells. Data are presentative of two independent experiments with at least n= 5-10 mice per group. 
Student t-test analysis **p< 0.01, ****p< 0.0001 was used to determine significance. 
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Figure 4.5: IL-4i1 deficiency promotes T-cell activation in naïve spleen. A) Representative 
section of H&E stained section (400x) of spleen tissue at F7 generation. Percentages of B) CD19+ 
B-cells. C) CD3+ T-cells, D) CD3+CD4+ T-helper cells, E) CD3+CD8+ cytotoxic T-cells, F) 
CD4+CD62L+CD44- T-helper cells, G) CD4+CD44+CD62L+ central memory T-helper cells, H) 
CD4+CD44+CD62L- Effector T-helper cells, I) CD3+CD4+Foxp3+ T-regulatory cells, J) 
CD4+CD62L+CD44- Cytotoxic T-cells, G) CD4+CD44+CD62L+ central memory cytotoxic T-cells, H) 
CD4+CD44+CD62L- Effector Cytotoxic T-cells, M) CD11b+Ly6G-F4/80+ macrophages, N) 
CD11b+CD11c+F4/80-Siglec F- dendritic cells and O) Geometric mean fluorescence of MHCII in 
macrophages are shown. Data are presentative of two independent experiments with at least n= 
5-10 mice per group. Student t-test analysis *p<0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 was 
used to determine significance. 
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Figure 4.6: IL-4i1 deficiency improves naïve lung pathology at steady state. Lung sections 
were isolated from naïve IL-4i1-/- and WT littermate controls at F7 and F9 generations. A) 
Representative section of H&E stained section (20) of lung tissue at F7 and F9 generation. 
Quantification of alveolar airspaces in B) F7 and C) F9 generation. Data are presentative of two 
independent experiments with at least n=3-4 mice per group. Student t-test analysis *p<0.05 was 
used to determine statistical significance. 
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Figure 4.7: IL-4i1 deficiency reduces frequency of total T-cell population; Foxp3+ 
regulatory T-helper cells at F9 generation in lungs. Percentages of A) CD19+ B-cells, B) CD3+ 
T-cells, C) CD3+CD4+ T-helper cells, D) CD3+CD8+ cytotoxic T-cells, E) CD4+CD62L+CD44- T-
helper cells, F) CD4+CD44+CD62L+ central memory T-helper cells, G) CD4+CD44+CD62L- Effector 
T-helper cells, H) CD3+CD4+Foxp3+ T-regulatory cells, I) CD4+CD62L+CD44- Cytotoxic T-cells. J) 
CD4+CD44+CD62L+ central memory Cytotoxic T-cells, K) CD4+CD44+CD62L- Effector Cytotoxic T- 
cells are shown. Data are presentative of two independent experiments with at least n= 5-10 mice 
per group. Student t-test analysis *p<0.05, **p< 0.01, ****p< 0.0001 was used to determine 
statistical significance. 
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Figure 4.8: IL-4i1 deletion did affect lung myeloid cell compartment but the expression of 
MHC II from antigen presenting cells Percentages of A) CD11b+Ly6G-F4/80+ macrophages, B) 
CD11b+CD11c+F4/80-SiglecF- dendritic cells, C) CD11b+CD11c+F4/80-SiglecF+ alveolar 
macrophages, and D) Geometric mean fluorescence of MHCII in macrophages cells are shown. 
Data are presentative of two independent experiments with at least n= 5-10 mice per group. 
Student t-test analysis *p<0.05 was used to determine significance. 
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Figure 4.9: IL-4i1 deficiency promotes in vivo proliferation of activated T-helper cells but 
reduces proliferation of Foxp3+ regulatory T cells in spleens. Frequency A) of Ki67 
expressing CD44+T-helper cells, B) Ki67 expressing Foxp3+ T-helper cells, C) Ki67 expressing 
CD4+ T-helper cells, D) Ki67 expressing Cytotoxic T-cells are shown. Data are presentative of two 
independent experiments with at least n= 5-10 mice per group. Student t-test analysis *p<0.05, 
**p< 0.01 was used to determine statistical significance. 
 
 
 
 
 
 
 
Figure 4.10: IL-4i1 deficiency promotes in vivo proliferation of Foxp3+ regulatory in lungs 
of WT littermate control and IL-4i1-/- mice. Frequency of A) Ki67 expressing Foxp3+ T-helper 
cells, B) Ki67 expressing CD44+T-helper cells C) Ki67 expressing CD4+ T-helper cells D) Ki67 
expressing cytotoxic T-cells are shown. Data are representative of two independent experiments 
with at least n= 5-10 mice per group. Student t-test analysis **p< 0.01 was used to determine 
significance
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Figure 4.11: IL-4i1 deficiency promotes differentiation of effector CD4+ T-cells. A) 
Frequencies of transcription factor expressing T-helper cells; T-bet CD4+ T-cells, Gata-3 CD4+ T- 
cells, Rorγt CD4+ T-cells, Foxp3+ expressing CD4+ T-cells respectively are shown. B) Frequencies 
of cytokine producing T-helper cells are presented. Data are representative of two independent 
experiments with triplicates per experiment. Student t-test analysis *p< 0.05 was used to determine 
significance. 
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Figure 4.12: IL-4i1 deficiency increases ex-vivo metabolic energy status of T-helper cells. 
A-B) Extracellular acidification and oxygen consumption rates of 5x105T-helper cells stimulated 
with 100U/ml IL-4 or left unstimulated isolated from spleens of WT littermate control and IL-4i1-/- 
mice. Data is from one experiment with triplicates per group. Student t-test analysis ***p< 0.001 
was used to determine significance. 
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Figure 4.13: IL-4i1 deficiency increased serum IFN-γ and TNF-α production at F7 but not at 
F9 generations. Serum levels of A) IL-12p70, B) IL-10 C), TNF-α, D) IFN-γ, E) IL-4 in WT and IL- 
4i1 deficient mice. Data are presentative of two independent experiments with at least n= 5-10 mice 
per group. Student t-test analysis *p<0.05, **p< 0.01 was used to determine significance. N.D= not 
detectable. 
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4.7  Summary 
 
 
 
 
 
 
 
 
Figure 10: Graphical representation of the role of IL-4i1 on immune homeostasis at steady 
state in vivo. 
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Chapter 5 
Manuscript in preparation 
IL-4i1 regulates macrophage mediated immune responses during 
acute Mycobacterium tuberculosis infection 
104  
Summary  
 
In this chapter we addressed possible targets of host-directed therapy for tuberculosis. 
Using  CAGE analysis, we selected candidate genes in polarized macrophages that 
might be used by Mtb to subvert immune responses. Here we selected IL-4i1, a 
candidate gene which was highly upregulated in M2 macrophages. This gene codes for 
an L-amino acid oxidase and was selected based on its T-cell immunoregulatory 
properties. We hypothesized  that the enzyme secreted by macrophages, upon release 
would limit T-cell responses that are responsible for Mtb killing. We used gene deficient 
mouse models to address the functional role of IL-4i1 on infectious immunity during Mtb 
infection. We showed that IL-4i1 deletion rendered mice resistant to both lab H37Rv and 
HN878 hypervirulent Mtb strains and that the role of IL-4i1 on Mtb infection is at early 
infection and is associated with macrophage responses not T-cells. We showed that IL-
4i1 deletion  promoted the recruitment of the “M1-like” which was accompanied by  
reduced bacterial burden and increased pro-inflammatory chemokine, IFN-γ and NO 
production macrophage phenotype. Thus showing an important immunoregulatory role 
for IL-4i1 during Mtb infection and that IL4i1 might be a  potential immunomodulatory 
target for host-directed therapy for tuberculosis. The PhD candidate performed all 
validation qPCR experiments in Figure 5.1 by herself. She performed bacterial burden, 
lung homogenates and  lung weight experiments in Figures  5.2 and 5.5 with Dr Mumin 
Ozturk and Mr Julius Chia. The candidate performed all flow cytometry experiments in 
Figure 5.2, 5.3, 5.4 and 5.6; Immunohistochemistry in Figure 5.2 and 5.5 and ELISA 
experiments in Figure 5.4 and 5.7 by herself.   
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5.1 Abstract 
 
Objectives: Mycobacterium tuberculosis (Mtb) resides in lung macrophages upon 
infection. Macrophages can be polarized into distinct classically M1(IFN-y) or 
alternatively M2) activated phenotype depending on the activation stimuli upon infection 
which then engages different responses relative to disease control and progression. Mtb 
has been reported to manipulate the transcriptional profile of the M2(IL-4 or IL-4/IL-13) 
macrophage for immune evasion strategies to promote its survival. The L-phenylalanine 
oxidase, IL-4i1 implicated in various tumours and other inflammatory disorders has 
recently been reported to drive macrophage polarization towards an alternatively 
activated  M2 phenotype. In our genome-wide transcriptional analysis of IFN-γ activated 
M1 macrophages, and IL-4 and IL-4/IL-13 activated M2 macrophages that were then 
infected with Mtb, high IL-4i1 transcripts were induced in M2 (IL-4 or IL-4/IL-13) and M2 
(IL-4 or IL-4/Il-13) infected macrophages. Other studies have reported the expression of 
IL-4i1 in TB lesions of patients with pulmonary tuberculosis and those with tuberculosis 
meningitis (TBM) co-infected with HIV when as well as in lungs of mice following 
aerogenic Mycobacterium tuberculosis (Mtb) infection. However, the role of IL-4i1 in host 
immunity to Mtb infection has not been investigated to date.  
 
Methods and Results: Here we investigated the role of IL-4i1 during Mtb infection. High 
mRNA expression of IL-4i was observed in M2 (IL-4 or IL-4/IL-13) macrophages infected 
with Mtb. In order to uncover a possible role of IL-4i1 in tuberculosis in vivo, we 
generated an IL-4i1-deficient mouse BALB/c strain  and infected with Mtb H37Rv or 
hyper-virulent HN878 Mtb strain and littermates control. IL-4i1 deficient mice were highly 
resistant to tuberculosis compared to littermate controls at 12 and 21 days post-infection. 
IL-4i1-/- had increased IFN-g and nitric oxide (NO) killing effector functions, leading to 
decreased bacteria in the lung with highly increased host protective chemokines CCL-5, 
CXCL-1 CXCL-5 as well as high recruitment of “M1-like” macrophages compared to 
littermate controls.  
 
Conclusions: Taken together, our findings suggested that at early infection, transient 
expression of IL-4i1 regulates macrophage-mediated immunity These data provide an 
indication of an immune regulatory role of IL-4i1 during Mtb infection. In conclusion, 
inactivation of IL-4i1 might be a potential immunomodulatory target for tuberculosis host-
directed therapy.  
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5.2 Introduction 
 
Classically activated macrophages characterized by the release of nitric oxide are 
essential for Mtb killing. Upon Mtb infection, recognition of PAMPS by PRR leads the 
release of NO via the MyD88-dependent signalling. Mice deficient of NOS-2 had increased 
arginase production and developed increased bacterial burden due to the absence of NO 
production [71, 78]. However, Mtb has found subverting strategies to this hostile 
environment. One mechanism is the induction of an M2-like environment. Recently, it was 
reported that Mtb induces arginase (Arg-1) production which competes with NOS2 for L- 
arginine substrate [80]. Macrophage polarization is important in the outcome of granuloma 
formation. The infiltration of M1 or M2 macrophages determines the type of granuloma 
that forms. Necrotic granulomas were associated with M1-like macrophages that are 
characterized by short NFκB signalling intervals in non-human primates [176]. Increased 
expression of CD206 mannose receptor associated with ‘’M2-like’’ macrophages in lungs 
was associated with caseating granulomas in TB patients. Genome-wide transcriptional 
analysis of IFN-γ activated M1 macrophages and IL-4 or IL-4/IL-activated M2 
macrophages infected with HN878 Mtb revealed IL-4i1 as one of the candidate genes 
upregulated in M2 (IL-4 or IL-4/Il-13)  macrophages suggesting a role for IL-4i1 during 
Mtb infection. The most characterized role of IL-4i1 is its immunomodulatory properties 
during inflammatory conditions which are mostly associated with its enzymatic activity 
[89]. Its major role is in limiting T-and B-cell activation and proliferation [90, 91, 93, 94]. 
Recently, IL-4i1 was reported to promote macrophage polarization towards an M2 
phenotype via STAT- 6/STAT-1 phosphorylation and partly through the depletion of L-
tryptophan and L-arginine which in-turn limited T-cell proliferation. However, the role of 
IL-4i1 in infectious immunity has not been investigated to date [92]. To determine the 
functional role of IL-4i1 during Mtb infection, we used gene knockout mouse models. We 
postulated that IL-4i1 expression by M2 (IL-4 or IL-4/Il-13)  macrophages would in-turn 
limit proliferation and activation of pro- inflammatory T-cells that are responsible for Mtb 
killing. Here we report on the role of IL- 4i1 in regulating macrophage mediated immune 
responses at early acute Mtb infection.
108  
5.3 Materials and Methods 
 
5.3.1 Mice 
 
IL-4i1 deficient mice (IL-4i1-/-), wild-type control littermates (IL4+/+) or wildtype BALB/c mice 
were used for this study. All experimental mice were matched for sex and age and used 
between 8-12 weeks of age. Mice were kept under pathogen-free conditions in individually 
ventilated cages at the University of Cape Town’s animal facility unit Biosafety level 2 
(BSL-2) or BSL-3. Animal room temperature was maintained at 22-25 ˚C and 12 hours 
light/dark cycle. Food pellets and water were made available ad libitum. 
5.3.2 Ethical Statement 
 
All experimental procedures were carried in accordance with the South African National 
Standard (SANS 10386:2008). The protocol (015/037) was approved by the Ethics 
Committee, University of Cape Town. 
5.3.3 Generation of BMDMs, MDMs, Mtb infection and quantitative expression of 
IL- 4i1 in macrophages 
BMDMs were generated from 8-12 weeks old BALB/c mice as described [127]. Following 
10 days of differentiation, BMDMs were cultured in triplicates overnight for adherence 
into 96-well plates (Nunc, Denmark) at 5 x 104 cells per well. Monocyte-derived 
macrophages (MDMs) were isolated from human peripheral nuclear cells (PBMCs) 
generated blood samples obtained from healthy donors. At 24hrs post adherence, 
BMDMs were stimulated with 100U/ml recombinant IFN-γ or 100U/ml IL-4 or IL-4/IL-13. 
Single cell suspension of hypervirulent HN878 Mycobacterium tuberculosis (Mtb) from 
frozen stock was prepared in DMEM media. After 24hr of stimulation or 24hrs post 
adherence for MDMs cells were infected with HN878-Mtb at MOI 1:5 CFU per well. Cells 
were then washed once with culture media to remove extracellular bacteria or lysed. 
Lysates were plated on 7H10 agar plates containing 10% OADC and 0.5% glycerol for 
CFU counting to determine bacilli uptake. At 2, 6, 12 and 24 hours post-stimulation, or 
4hr, 12hr, 24hrs or 48hrs post-infection, cells were lysed with 1 ml of Qiazol and total RNA 
will be extracted by RNAeasy kit from Qiagen from which cDNA was synthesized using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche) according to manufacturer’s 
instructions. Real-time PCR was performed with LightCycler® 480 SYBR Green I Master 
mix in LightCycler® 480 II (Roche). A time-course quantitative expression analysis of IL-
4i1 normalized against the housekeeping gene Hprt with primers, IL-4i1 forward 5’ 
ATTCCCCAGAGGACATCTACCA and reverse 5’ CTGTACCGGAGTCTATCGCTCA.  
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5.3.4 In vivo Mtb infection and quantitative tissue expression of IL-4i1 
 
Mice were infected with hypervirulent HN878 or H37Rv laboratory Mtb strains at 100 per 
mouse via intranasal route as described in [17]. Quantitative real-time RT-PCR of total 
murine RNA extracted by RNAeasy kit from Qiagen was reverse transcribed by 
Transcriptor First Strand cDNA Synthesis Kit (Roche) according to manufacturer’s 
instructions. Real-time PCR was performed with LightCycler® 480 SYBR Green I Master 
mix in LightCycler® 480 II (Roche). Quantitative tissue expression analysis of IL-4i1 was 
normalized against the housekeeping gene Hprt1 with primers , IL-4i1 forward 5’ 
ATTCCCCAGAGGACATCTACCA and reverse 5’ CTGTACCGGAGTCTATCGCTCA. 
5.3.5 Flow Cytometry 
 
Single cell suspensions from infected lung tissues were stained for surface markers with 
the following antibodies: F4/80 (PE-cy7) from Affymetrix eBiosciences; CD4 (PercCP-cy 
5.5 or PE or FITC); CD11c (V450 or A700 or APC); CD11b (PercCP-cy 5.5); MHCII 
(A700); CD103 (PE); SiglecF (APC-cy7 or APC); CD44 (FITC); CD62L (V450); CD19 
(PercCP-cy5.5); CD8 (V500); LY6G (APC-cy7); Foxp3 (APC); CD 80 (V450); CD206 
(FITC) and Ki67 (PE) from BD Biosciences in FACS buffer. Rabbit polyclonal IL-4i1 
antibody was purchased from Abcam and goat anti-rabbit secondary IgG (PE) purchased 
from (Abcam). For surface staining, cells (1x106) were labelled and washed with PBS 
containing 0.1% BSA (Rosche, Switzerland) and 0.1% NaN3. For intracellular staining, we 
used the BD Pharmingen Transcription Buffer Set (BD Biosciences) as per manufacturer’s 
instructions to detect Foxp3 and Ki67 expression. Acquisition was conducted using BD 
LSR Fortessa (BD Biosciences Immunocytochemistry systems), and data analysis was 
performed with FlowJo software (Treestar, Ashland, OR, US). 
5.3.6 Histology 
 
Formalin fixed (4%) Mtb-infected lungs from wild-type littermate controls and IL-4i1-/- 
mice were stained with hematoxylin and eosin or rabbit anti-mouse iNOS (Abcam) and 
detection performed using HRP-labelled anti-rabbit and anti-goat, respectively as 
described [80, 151]. Gelatine-based mounting medium was used to mount the sections. 
Image acquisition and quantification of alveolar airspaces, iNOS and Arg1 were 
performed using NIS advanced software on a Nikon (Tokyo, Japan) 90i microscope. 
Percentage of free alveolar airspaces was defines as the area of ventilated spaces in 
whole lung sections in relation to the total lung tissue area using the area measurement 
tool by NIS advanced software on a Nikon 90i microscope and % alveolar spaces 
calculated using Excel as described [21]. The percentage of iNOS and Arg1 was 
performed using a blinded quantification method as described [21]. 
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5.3.7 The enzyme-linked immunosorbent assay 
 
Blood samples from IL-4i1-/- and wild-type littermate controls were collected by cardiac 
puncture upon sacrifice. Serum samples were used to determine systemic cytokine and 
chemokine production using enzyme-linked immunosorbent assay. IL-1β, IL-12p40, IL- 
12p70, TNF-α, IL-2, IL-10, IFN-γ, IL-4, CCL-2, CCL-3, CXCL-1, CXCL-2, CXCL-5 and 
CCL-5 (All from BD Biosciences) production was measured from the supernatants and 
data analysed using SoftMax Pro 6. 
5.3.8 Statistical Analysis 
 
All data were analysed using Graph-Pad Prism 6.0, student t-test (two-tailed with equal 
variance) was used. A *p value of less 0.05 was considered significant, with **p < 0.01, 
***p < 0.001 and ****p < 0.0001. 
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5.4 Results 
 
5.4.1 Identification of IL-4i1 expression during Mtb infection. 
 
To confirm CAGE identified expression of IL-4i1 in macrophages. Bone marrow-derived 
macrophages from WT BALB/c mice were subjected to polarization to classically (M1) or 
alternatively activated (M2) macrophages following stimulation with IFN-γ and IL-4; IL- 
4/IL-13 respectively. Subsequent to stimulation, mice were infected with HN878 Mtb 
strain. Time-course mRNA expression of IL-4i1 was determined by qPCR. Early transient 
expression of IL-4i1 was observed at 6 hrs post-stimulation in IL-4 stimulated alternative 
activated macrophages. Infection with Mtb induced IL-4i1 at 12 hrs post- infection 
(Figure 5.1A). Time-course expression of IL-4i1 was measured in human monocyte-
derived macrophages from healthy donors following HN878 Mtb infection. IL-4i1 
expression was maintained at 1.5-2 fold higher throughout 48hrs study when compared 
to 0hrs (Figure 5.1B). In vivo expression of IL-4i1 was determined in lungs of BALB/c 
mice intranasally infected with HN878 Mtb strain. Mtb infection showed a trend towards 
increased expression at 21 days post-infection (Figure 5.1C). Different types of human 
TB granulomas showed differential levels of IL-4i1 expression (Figure 5.1D). Previously, 
granulomas biopsies from TB patients have shown high expression of IL-4i1 in areas 
enriched with myeloid antigen presenting cells, macrophage and dendritic cells. Taken 
together, these data suggest a role for IL- 4i1 during Mtb infection. However, a role of IL-
4i1 in infectious immunity has not been investigated to date. We thus sort to investigate 
the role on immune regulation during Mtb infection using IL-4i1 gene-deficient mouse 
model. 
 
5.4.2 IL-4i1 deletion reduces bacterial burden and histopathology during acute 
H37Rv infection. 
Control littermate (WT) and IL-4i1 deficient mice (IL-4i1-/-) were infected intranasally with 
100 H37Rv Mtb strain and bacterial burden measured by colony forming units were 
measured at 21 days post-infection. Bacterial burdens were significantly reduced in lungs 
of IL-4i1-/- mice compared to WT (p< 0.01) (Figure 5.2A). Lung weights were not affected 
(Fig 2B). Total lung cell numbers showed a trend of reduction (Figure 5.2C). Frequency of 
total and total number of infiltrating CD3+ T-cells was not affected (Figure 5.2D and E). 
Histopathology analysis showed significantly reduced granulomas (p< 0.05) (Figure 5.2F 
and H) and significantly less iNOS expression in infected lungs (Figure 5.2G and I). 
These data suggest that the reduced histopathology is a result of the reduced bacterial 
burden, further suggesting that IL-4i1 deletion promotes resistance to infection.
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5.4.3  IL-4i1 deletion does not influence adaptive immune responses, but reduces 
inflammatory macrophage recruitments and increases NO production. 
The major characterized role of IL-4i1 is in the activation and proliferation of T-cells and 
recently of B-cell activation. To determine cellular infiltration in the lungs, we determined 
different adaptive cell populations by flow cytometry in the lungs 21 days-infection with 
H37Rv infection. There were no differences in B and T-cells and the different subsets nor 
their proliferative status between WT and IL-4i1-/- (Figure 5.3A-F). IL-4i1 deletion 
significantly reduced interstitial macrophage recruitment compared to WT (p<0.05) 
(Figure 5.4A-B). Pro-inflammatory cytokine production measured from lung supernatants 
showed a trend towards reduction (Figure 5.4C). The cytokine IL-12 produced by both 
macrophages and dendritic cells responsible for the activation of Th1 pro-inflammatory 
responses was reduced in IL-4i1-/- compared to WT mice (Figure 5.4C). The reduction 
correlated with the reduction in interstitial macrophages as dendritic cell population was 
not affected. Interestingly, a significant increase in nitric oxide production was observed 
at 21 days post-infection in IL-4i1-/- compared to WT mice (Figure 5.4D). Similarly to 
cytokine production, we observed a significant reduction in pro-inflammatory chemokines 
CXCL-1 (p<0.001) and CXCL-2 (p<0.05) responsible for neutrophils and monocytes 
(Figure 5.4E) in IL-4i1-/- compared to WT mice. These data suggest a regulatory role of 
IL-4i1 in macrophage responses during Mtb infection which contribute to the reduced 
CFU burden as a result of IL-4i1 deficiency. 
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5.4.4 IL-4i1 deletion renders resistance to HN878 Mtb infection by promoting the 
recruitment of “M1-like” restrictive macrophages as early as 12 days post-infection. 
To determine the role of IL-4i1 on macrophage mediated immune responses, we 
intranasally infected mice with 100 CFU hypervirulent strain previously used in CAGE 
macrophage atlas experiments. Mice were sacrificed at 12 days post-infection, a time- 
point were only innate immunity takes place and 21 days post-infection after adaptive 
immunity is established during Mtb infection. IL-4i1 deletion significantly reduced bacterial 
burden at 12 and 21 days post-infection (Figure 5.5A) while lung weights were not 
affected (p<0.05) (Figure 5.5B). These data suggest a regulatory role of IL-4i1 in 
macrophage responses during Mtb infection which contribute to the reduced CFU burden 
as a result of IL-4i1 deficiency with no differences in lung weight (Figure 5.5A-B). 
Histopathology H&E analysis showed no differences in alveolar airspaces between WT 
and IL-4i1-/- at 12 post- infection (Figure 5C-D). Contrary to H&E and iNOS reduced 
histopathology observed in IL-4i1-/- during H37Rv infection 21 days post-infection, no 
differences were observed in mice infected with HN878 infected while iNOS expression 
was significantly (p< 0.05) increased at 21 days post-infection (Figure 5.5E-H). 
Previously, IL-4i1 has been reported to promote macrophage polarization towards M2 
phenotype in vitro via STAT-6 phosphorylation and partly through its role in arginine 
depletion towards arginase production. To determine the role of IL-4i1 on macrophage 
polarization in vivo, different populations of myeloid cells were determined by flow 
cytometry in lungs of WT and IL-4i1-/- infected with 100 CFU HN878. There were no 
differences in myeloid cell populations between WT and IL-4i1-/- mice (Figure 6A-B). We 
next determined the number of ‘”M1-like” restrictive and “M2-like” permissive 
macrophages infiltrating the lung. There we no differences in MHCII+ CD206+ M2-like 
permissive alveolar macrophages, MHCII+CD80+ M1-like alveolar macrophages. GMFI 
expressions of CD 206+ and CD 80+ in alveolar macrophages were not affected  in IL-4i1-/- 
compared to WT (Figure 6C-E). Interestingly, percentages and total cell numbers of M2-like 
CD 206 interstitial macrophages were reduced in IL-4i1-/- compared to WT mice, while 
and the opposite effect was observed for M1-like CD80+ interstitial macrophages (Figure 
6F-G). No differences were observed in GMFI expressions of CD 206+ and CD 80+ in 
interstitial macrophages between WT and IL-4i1-/- mice (Fig H-I). Lung production of pro-
inflammatory cytokines (IL-1β, IL-6, TGF-β) showed an increase towards increased 
levels while pro-inflammatory chemokines (CCL-2, CCL-3, CXCL-1, CXCL-2, CXCL-5, 
CCL-5) were enriched by IL-4i1-/- deletion. Taken together, these data suggest that IL-4i1 
deletion leads to increased pro-inflammatory macrophage immune responses that are 
characterized by “M1-like” phenotype that promote NO production leading to reduced 
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bacterial burden at early Mtb infection. 
 
 5.5 Discussion 
 
Our mRNA expression data in infected M2 (IL-4 or IL-4/IL-13) BMDMs, MDM and 
acute Mtb infection in mice showed an early transient expression of IL-4i1 (Figure 1 
5.1A-B) suggesting that Mtb may induce the expression of IL-4i1 for protection from 
pro-inflammatory macrophage killing suggesting an immune regulatory role during 
Mtb infection. Granuloma expression of IL-4i1 in TB patients substantiates this claim. 
Immunohistochemistry of lung biopsies from TB infected patients previously showed 
that the expression of IL-4i1 was restricted to areas that were macrophage and 
dendritic cells enriched [86]. To determine the role of IL-4i1 on immune responses 
during Mtb, we used gene deficient mice models. IL-4i1 deficiency rendered mice 
resistant to H37Rv and HN878 Mtb infection at 21 days post-infection as denoted by 
reduced bacterial burden and reduced histopathology with less infiltrating 
inflammatory T-cells (Figure 5.2). These data suggested that immunohistopathology 
was associated with the reduced bacterial burden. Surprisingly, T-cell mediated 
immune responses had no influence of the infection outcome (Figure 5.3). 
Interestingly, we observed reduced infiltration of CD11b+ F/480+ interstitial 
macrophages in the lungs at 21 days post-infection, but increased lung NO 
production (Figure 5.4), suggesting that IL-4i1 had a role on macrophage mediated 
immune responses during acute infection. To determine the role of IL-4i1 on 
macrophage mediated responses, we infected mice with HN878 for 12 days, a time-
point where only the innate immunity was established. Bacterial burden was reduced 
as early 12 days post-infection in IL-4i1 deficient mice (Figure 5.5). We observed an 
increase in “’M1-like’’ MHCII+ CD80+ restrictive macrophages in IL-4i1-/- compared to 
MHCII+CD 206+ permissive macrophages (Figure 5.6) which in-turn promoted an 
increase pro-inflammatory cytokines and chemokines (Figure 5.7), suggesting that IL-
4i1 regulates macrophage mediated responses. These findings are in line with 
Psachoulia et al. [95] findings on remyelination. Immunohistochemistry of the brain 
revealed that CD 11b+ infiltrating cells were iNOS enriched in the absence of IL-4i1. 
Furthermore, Monin et al. [177] showed that S. mansoni induced arginase reduced 
tupe-1 infiltration F/480+ cells in lungs of different mouse models. “M1-like” and ‘’M2-
like” macrophages distinct metabolic statuses. Mtb strives permissive macrophages 
which are characterized by fatty acid oxidation while restrictive macrophages are 
highly glycolytic [178]. It is possible that Mtb induces IL-4i1 early upon infection to 
promote the infiltration of M2-like permissive macrophages for its protection. It is 
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important to note that these cell numbers are very low to suggest that this is solely the 
mechanism by which IL-4i1 regulated immune responses during Mtb infection. 
However, these data may suggest a contributing mechanism. Furthermore, these 
data are indicative of the differential possible role of IL-4i1 within the context of the 
same infectious model. At early infection, transient expression of IL-4i1 regulates 
macrophage-mediated immunity while at chronic phase may be involved in T-cell 
mediated immunity. These provide an indication of a possible immunoregulatory role 
for IL-4i1 during Mtb infection making it a possible immunomodulatory target for host-
directed therapy for tuberculosis. 
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Figure 5.1: mRNA expression of IL-4i1 during Mycobacterium tuberculosis infection: A) 
Bone marrow-derived macrophages were infected with HN878 Mtb strain following macrophages 
polarization to IFN-γ (classically activated, M1) or IL-4 or IL-4/IL-13 (alternatively activated, M2) 
macrophages. Time-course expression of IL-4i1 was determined by qPCR normalized to HPRT1. 
B) Time-course IL-4i1 expression from human monocyte-derived macrophages infected with 
HN878 Mtb. C) IL-4i1 expression from lung tissues of BALB/c mice intranasally infected with HN878 
at 11 and 21 days post-infection relative expression in naïve mice (n=3). D) Hit-map of IL-4i1 
expression TB granulomas. 
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Figure 5.2: IL-4i1 deficient mice were resistant to H37Rv Mtb infection with reduced 
pathology and cellular infiltration. Control littermate (WT) and IL-4i1 deficient mice (IL-4i1-/-) 
(n=5) were infected intranasally with 100 H37Rv Mtb strain. Mice were sacrificed 21 days post-
infection. A) Bacterial burden in lungs of infected mice. B) Lung weights of infected mice. C) Total 
cell numbers from single cell suspensions of infected lung tissues. D) Percentage and E) Total cell 
CD3+ T-cells infiltrating the infected lung tissues measured by flow cytometry. F) Representative 
histopathology sections (×20) at 21 days post infection for H&E sections. G) Representative iNOS 
sections (×20) at 21 days post infection. H) Lung granulomas were quantified by measuring area 
of solid tissue vs ventilated airspaces from 4 deep cuts H&E lung sections per mice (30μM apart) at 
3 weeks post- infection. I) iNOS staining per lung section was quantiﬁed from 1–2 deep cut lung 
sections per mice at 3 weeks p.i. (30µm apart). Data are representatives of 3 independent 
experiments. Error bars show mean±SEM. Student’s t-test *P<0.05; **P<0.01 was used to 
determine significance. 
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Figure 5.3: IL-4i1 deletion did not influence adaptive immune responses at 3 weeks post 
H37Rv-Mtb infection. Control littermate (WT) and IL-4i1 deficient mice (IL-4i1-/-) (n=5) were 
infected with 100 H37Rv Mtb strain. Mice were sacrificed 21 days post-infection to determine 
adaptive immune responses to infection. A) Percentage and total cell numbers of CD3+CD4+ T-
cells and CD3+CD8+ T-cells in lungs of infected mice. B) Percentage and total cell numbers of 
CD19+ B-cells in lungs of infected mice. C) Percentage and of CD4+ CD62L+ naïve T-cells; 
CD4+CD44+CD62L+ central memory T-cells; CD4+CD44+ effector T-cells. D) Percentage and of 
CD8+CD62L+ naïve T-cells; CD8+CD44+CD62L+ central memory T-cells; CD8+CD44+ effector T-
cells measured by flow cytometry. E) Percentage CD 4+ regulatory T-cells. F) Percentage of 
proliferating Ki67+ CD4+CD44+ effector T-cells. Data are representatives of 3 independent 
experiments. Error bars show mean±SEM. Student’s t-test *P<0.05 was used to determine 
significance. 
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Figure 5.4: IL-4i1 deletion reduces interstitial macrophage recruitment in infected lungs 
but increases nitric oxide production in H37Rv-Mtb infected lungs. Control littermate (WT) 
and IL-4i1 deficient mice (IL-4i1-/-) (n=5) were infected with 100 H37Rv Mtb strain. Mice were 
sacrificed 21 days post- infection to determine innate immune responses to infection. A) 
Percentage myeloid cell populations (CD11c+SiglecF+ Alveolar macrophages; CD11b+F/40+ 
Interstitial macrophages; CD11b+CD11c+MHCII+ Dendritic cells; CD11c+CD103+MHCII+ Migratory 
dendritic cells) in infected lungs. B) Total cell numbers of myeloid cell population (CD11c+Siglec 
F+ Alveolar macrophages; CD11b+F/40+Interstitial macrophages; CD11b+CD11c+MHCII Dendritic 
cells; CD11c+CD103+MHCII+ Migratory dendritic cells) in infected lungs. C) Lung cytokine 
production determined from lung homogenates. D) Nitric oxide production from infected lung 
homogenates. E) Lung chemokine production determined from lung homogenates. Data are 
representatives of 3 independent experiments. Error bars show mean±SEM. Student’s t-test 
*P<0.05; **P<0.01; P< 0.001) as used to determine significance. 
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Figure 5.5: IL-4i1 deficient mice were resistant to early HN878-Mtb infection. Control 
littermate (WT) and IL-4i1 deficient mice (IL-4i1-/-) (n=5) were infected intranasally with 100 
hypervirulent H37Rv Mtb strain. Mice were sacrificed at 12 and 21 days post-infection. A) 
Reduced bacterial burden in lungs of infected mice at both 12 and 21 days post-infection. B) Lung 
weights of infected mice. C) Representative histopathology sections (×20) at 12 days post 
infection for H&E sections. D) Lung alveolar ventilated airspaces were quantified from 4 deep cuts 
H&E lung sections per mice (30μM apart) at 12 days post-infection. E) Representative 
histopathology sections (×20) at 21 days post-infection for H&E sections. F) Lung alveolar were 
ventilated airspaces quantified from 4 deep cuts H&E lung sections per mice (30μM apart) at 21 
days post-infection G) Representative iNOS sections (×20) at 21 days post-infection. H) iNOS 
staining per lung section was quantiﬁed from 1–2 deep cut lung sections per mice at 21 days 
post-infection (30µm apart). Error bars show mean±SEM. Student’s t-test *P<0.05; ***P<0.001 
was used to determine significance. 
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Figure 5.6: IL-4i1 deficiency promotes recruitment of “M1-like” restrictive macrophages at 
early HN878-Mtb infection. Control littermate (WT) and IL-4i1 deficient mice (IL-4i1-/-) (n=5) were 
infected intranasally with 100 hypervirulent H37Rv Mtb strain. Mice were sacrificed at 12 post- 
infection to determine innate immune responses to infection. A) Total numbers and percentages of 
myeloid cell populations (CD11b+Ly6G+ neutrophils; CD11c+SiglecF+ Alveolar macrophages; 
CD11b+F/40+ Interstitial       macrophages;       CD11b+CD11c+MHCII+ Dendritic cells; 
CD11c+CD103+MHCII+ Migratory dendritic cells) in infected lungs. B) Percentage and total 
numbers of CD11c+Siglec F+MHII+CD206+ alveolar macrophages. C) Percentage and total 
numbers of CD11c+SiglecF+MHII+CD206+ alveolar macrophages. C) Percentage and total numbers 
of CD11c+SiglecF+MHII+CD80+ alveolar macrophages. D) GMFI of CD206+ in alveolar 
macrophages. E) GMFI of CD80+ in alveolar macrophages. F) Percentage and total numbers of 
CD11b+F/480+MHCII+CD206+ interstitial macrophages. G) Percentage and total numbers of 
CD11b+F/480+MHCII+CD80+ interstitial macrophages. H) GMFI of CD206+ in interstitial 
macrophages. I) GMFI of CD80+ in interstitial macrophages. Data are representatives of 
mean±SEM. Student’s t-test *P<0.05; **P<0.01; P<0.001 was used to determine significance. 
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Figure 5.7: IL-4i1 deficiency promotes pro-inflammatory chemokine production. Control 
littermate (WT) and IL-4i1 deficient mice (IL-4i1-/-) (n=5) were infected intranasally with 100 
hypervirulent HN878 Mtb strain. Mice were sacrificed at 12 days post-infection to determine A) 
cytokine, B) chemokine production in infected lung homogenates during infection. Data are 
representatives of mean±SEM. Student’s t-test *P<0.05; **P<0.01 was used to determine 
significance. 
 
 
5.6 Summary 
 
 
 
Figure 5.8: Graphical representation of the role of IL-4i1 during early Mycobacterium 
tuberculosis infection. 
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             Chapter 6 
                                                       Conclusions 
 
The aim of the study presented in this thesis was to identify potential drug targets for 
pathogen- and host-directed therapy for tuberculosis. TB remains a major public health 
global challenge. The shortage of effective drugs and vaccines, with the emergence of 
MDR and XDR TB, propels an urgent need for new effective therapeutics. The STOP-TB 
partnership has set goals to eradicate TB by 2050. Their goals include developing new 
effective drugs, vaccines, diagnostics and vaccines. It is imperative to develop treatment 
approaches that focus on both the pathogen and the host. The development of new 
effective drugs lies primarily on understanding host-pathogen interactions and the 
possible mechanisms by which the pathogen can invade or subvert host immune system 
through molecular approaches. These approaches would help identify possible targets 
that may be used by Mtb to subvert cellular transcriptional landscape especially 
macrophages which are the first contact for Mtb. 
 
In this study we addressed the role of MGBs that target the AT-rich regions of the minor 
groove of pathogenic DNA as a potential target for pathogen-directed therapy. We further 
addressed the importance of using a reliable delivery system (NIVs) for effective 
treatment. MGBS bind to pathogenic DNA and inhibit DNA replication. The anti-infective 
activity of Strathclyde MGBs has been previously reported against many pathogens [25, 
26, 29-31, 34-36, 106, 113, 116]. The specificity of binding affinity and cell wall 
permeability for is mostly associated with the structure of the head and tail groups of the 
compound. From the list of the compounds we screened, we identified hit compounds that 
were effective against Mtb in vitro. Proof of concept studies in mice showed in vivo activity 
of one of the compounds, MGB 364 at low concentrations. The use of NIVs improved the 
activity of these compounds. From these studies we could conclude on the potential of 
MGB 364 as a lead compound against Mtb infection. Interestingly we also observed that 
intranasal administration of MGB-NIV 364 formulation improved immune responses and 
pathology during Mtb infection. With this we could conclude on the possibility of an adjunct 
TB therapy while using NIVs. In this case NIVs would be effective in delivering the drug of 
interest as well as trigger immune activation necessary for killing of the pathogen. 
However, this would need controlled measures to ensure that the effects are not 
detrimental to the host. The limitations of the study is the availability of the compound to 
perform further experiments due to delay in synthesis process. Future studies include 
testing in vivo efficacy of MGB-364 using lower dose of Mtb for infection as well as low 
(0.5 mg/kg) and high (10 mg/kg) doses of MGB-364 via intranasal and oral routes of 
administration. We aim to further identify specific targets of these MGB 364 through the 
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creation of mutant strains and also addressing the possible mechanism by which MGB 
364 kills Mtb. The use of extracellular vesicles from Mtb infected macrophages have been 
reported to carry Mtb RNA that triggers IFN-β signaling pathway as well as improved 
activity of moxifloxacin when used as an adjunct therapy [48]. It would thus be essential 
to investigate the signaling pathway triggered by NIVs to elicit an immune response. 
 
To address possible targets for host-directed therapy, the aforementioned CAGE analysis 
was used to select candidate genes in macrophages that might be used by Mtb to subvert 
immune responses based on the initial hypothesis. Our initial hypothesis was that Mtb 
uses or alters M2 transcriptional landscape to hide away from M1 macrophage effector 
killing. Here we selected IL-4i1, a candidate gene highly upregulated in M2 macrophages. 
This gene codes for an L-amino acid oxidase and was selected based on its T-cell 
immunoregulatory properties. We postulated that the enzyme secreted by macrophages, 
upon release would limit T-cell responses that are responsible for Mtb killing. We used 
gene deficient mouse models to address the functional role of IL-4i1 during Mtb infection. 
We first investigated the role of the gene at steady-state and whether gene deletion would 
not cause any systemic impairments. We used the “reverse F2 strategy” to eliminate the 
flanking gene confounders. We noticed systemic dysregulation at early generations of 
mouse breeding which stabilized at F9 congenic background. At F9 we could 
unprecedentedly show the role of IL-4i1 on activation and proliferation of CD 4 T-cells in 
spleen and lungs at steady-state in vivo. We thus could see that IL-4i1 is important for 
immune homeostasis and that null mutation or deletion could lead to autoimmunity. These 
data are indicative of IL-4i1 hypo-mutation as a potential causative of autoimmunity. We 
then addressed the role of IL-4i1 on infectious immunity during Mtb infection. We showed 
that IL-4i1 deletion rendered mice resistant to hypervirulent Mtb strain and that the role of 
IL-4i1 on Mtb infection is at early infection and is associated with macrophage responses 
not T-cells during acute Mtb infection as initially postulated. We showed that IL-4i1 
promotes the recruitment of the M2 macrophage phenotype. These data are in synergy 
with the previous findings on the role of IL-4i1 in M2 polarization via the IL-4Rα signaling 
and STAT-6 signaling pathways and also the oxidization of L-arginine and L-tryptophan. 
It has also previously been shown that the M2 macrophage is permissive for Mtb survival. 
However, it has been shown that the IL-4Rα signaling in macrophages in vivo has no 
effect on the outcome of Mtb burden. However, hypervirulent Mtb can induce arginase 
production to trigger an M2 polarized environment. We thus concluded that Mtb promotes 
expression of IL-4i1 for its part role in oxidizing L-arginine to produce Arg1 promotes the 
polarization of M2 phenotype and related immune responses. We thus showed IL-4i1 as 
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potential target during Mtb infection. Future studies to address the mechanism underlying 
the role of IL-4i1 during Mtb infection may include transcriptional and metabolomic 
targeting approaches on the enzymatic activity of IL-4i1 during Mtb infection. 
 
In conclusion, our work provides a framework for possible new drug targets for effective 
TB therapy, providing a stepping-stone towards the development of new drugs and 
vaccines. This work thus significantly contributes to combating the world’s most prevalent 
and life-threatening disease, TB. 
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Appendix 
 
List of FACS and ELISA antibodies used 
 
Antibody Conjugate Type Company Catalogue 
number 
Dilution used 
CD3 A700 Hamster anti- 
mouse 
BD Biosciences 557984 1:160 of 0.2 
mg/ml 
CD4 FITC Rat anti-mouse BioLegend 100510 1:640 of 
0.5mg/ml 
CD8 V500 Rat anti-mouse BD Biosciences 560776 1:320 of 
0.2mg/ml 
CD11b V450 Rat anti-mouse BD Biosciences 560455 1:640 of 
0.2mg/ml 
CD11c A700 Hamster anti- 
mouse 
BD Biosciences 560583 1:320 of 
0.2mg/ml 
F4/80 PE-cy7 Rat anti-mouse Affymetrix 
eBioscience 
25-4801-82 1:320 of 
0.2mg/ml 
Siglec-F APC Rat anti-mouse BD Biosciences 562680 1:160 of 
0.2mg/ml 
Ly6G APC-Cy7 Rat anti-mouse Sony 
Biotechnology Inc 
1238120 1:640 of 
100µg/ml 
IL-4i1 Polyclonal Rabbit anti-goat BD Biosciences 553081 1:320 of 
0.2mgml 
Foxp3 APC Rat anti-mouse BD Pharmigen 560401 1:50 of 
0.5mg/ml 
CD19 PercCP-cy 
5.5 
Rat anti-mouse BD Pharmigen 551001 1:640 of 
0.5mg/ml 
CD62L V450 Rat anti-mouse BD eBioscience 560507 1:640 of 
0.5mg/ml 
CD4 PercCP-cy 
5.5 
Rat anti-mouse BD Pharmigen 5530252 1:640 of 
0.5mg/ml 
CD44 FITC Rat anti-mouse BD Biosciences 553133 1:640 of 
0.5mg/ml 
Ki67 PE Mouse anti-human BD Biosciences 556027 1:50 
MHC II A700 Anti-mouse eBiosciences 565321 1:640 
CD4 PE Anti-mouse eBiosciences 120041-82 1:640 
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Ly6C PercCP-cy 
5.5 
Rat anti-mouse BD Pharmigen 560525 1:160 
CD11c APC Hamster anti- 
mouse 
BD Pharmigen 550261 1:320 
Siglec F APC-cy7 Rat anti-mouse BD Biosciences 565527 1:320 
Ly6G FITC  BD Pharmigen 551460 1:320 
Streptavidin Texas Red  BD Biosciences 562284 1:1000 
CD103 PE  BD Biosciences  1:160 
NK.1.1 APC-cy7 Mouse anti-mouse BD Biosciences 560618 1:160 
CD 206 FITC Anti-mouse Biolegend 141703  
CD11b PercCP-cy 
5.5 
Rat anti-mouse BD Pharmigen 5509993  
CD80 V450  BD Horizon 566285  
 
 
Cytokine or 
antibody 
 Company Catalogue 
number 
Dilution used Clone 
 
 
 
IFN-gamma 
Primary Home-made 
(UCT) 
 1:500 Of 
3.4782 mg/ml 
AN18.KL6 
secondary BD 554410 1:1000 Of 
0.5mg/ml 
 
Standard BD 554587 200ng/ml  
 
 
 
TNF-alpha 
Primary BD 551225 1:500 of 
0.5mg/ml 
 
secondary PharMingen 1B122D 1:500 Of 
0.5mg/ml 
 
Standard BD Bioscience 554589 200ng/ml  
 
 
TGF-beta 
Primary BD 555052 1:250 Of 
0.5mg/ml 
A75-2 
secondary BD 555053 1:500 Of 
0.5mg/ml 
A75-3 
Standard WhitSci 240-B-002 100ng/ml  
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IL-1 alpha 
Primary BD 550604 1:250 Of 
0.5mg/ml 
 
secondary BD 550606 1:500 Of 
0.5mg/ml 
 
Standard WhitSci 400-ML-005 100ng/ml  
     
IL-1 beta Primary R&D systems    
secondary R&D systems    
Standard R&D systems    
Primary Home-made 
(UCT) 
 1:500 Of 
2.065mg/ml 
11B11 
 
 
 
IL-4 
secondary BD 554390 1:1000 Of 
0.5mg/ml 
 
Standard BD 550067 100ng/ml  
Primary BD 554400 :1:250 Of 
0.5mg/ml 
 
IL-6 secondary BD 554402 1:500 Of 
0.5mg/ml 
 
Standard BD Bioscience 554582 100ng/ml  
Primary WhitSci MAB417-500 1:500 Of 
500µg 
JES052A5 
IL-10 secondary Biocom Biotech 504906 1:1000  
Standard WhitSci 417-ML-005 100ng/ml  
Primary Biolegend 506902 1/500 Of 
500µg 
 
IL-17 secondary Biolegend 507022 1/500 Of 
50µg 
 
Standard WhitSci 421-ML-025 100ng/ml  
     
IL-12p40 secondary     
Standard R&D systems 49-ML-025   
Primary     
IL-12p70 secondary     
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 Standard BD 554592   
Primary     
 
 
 
 
 
